k141_635325_33	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	27.1	793	962	1024	3.43e-86	297
k141_635325_33	SARG|gb|CAA53189|ARO:3000521|mupA	27.1	793	962	1024	3.43e-86	297
k141_635325_33	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	27.1	793	962	1024	4.70e-86	297
k141_635325_33	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	27.1	793	962	1024	4.70e-86	297
k141_635325_33	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	27.8	802	962	1033	8.16e-84	291
k141_635325_33	SARG|gb|AEY83581|ARO:3000510|mupB	27.8	802	962	1033	8.16e-84	291
k141_635325_33	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	24.6	913	962	1107	6.12e-68	246
k141_635325_33	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	24.6	913	962	1107	6.12e-68	246
k141_635325_39	CARD|gb|AAC73788.1|ARO:3003841|kdpE	52.5	223	228	225	1.76e-77	231
k141_635325_39	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	52.7	220	228	225	3.55e-77	231
k141_635325_39	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.8	227	228	229	8.25e-48	156
k141_635325_39	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.4	224	228	231	1.24e-44	148
k141_635325_39	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.8	227	228	233	5.21e-44	146
k141_635325_39	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.5	226	228	232	7.15e-44	146
k141_635325_39	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.5	226	228	232	7.15e-44	146
k141_635325_39	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.8	224	228	231	9.82e-44	145
k141_635325_39	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.8	221	228	228	2.55e-43	144
k141_635325_39	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.0	223	228	230	2.69e-43	144
k141_635325_40	CARD|gb|CYF42523.1|ARO:3004047|kdpD	26.1	498	535	885	5.76e-36	142
k141_635325_40	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.1	241	535	392	2.06e-10	61.6
k141_635325_40	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.1	227	535	381	2.54e-09	58.2
k141_635325_40	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.1	227	535	381	2.54e-09	58.2
k141_635325_40	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.2	227	535	381	7.88e-09	56.6
k141_635325_40	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.2	227	535	381	7.88e-09	56.6
k141_635325_40	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.7	210	535	381	1.39e-08	55.8
k141_635325_40	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.7	210	535	381	1.39e-08	55.8
k141_635325_40	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.7	206	535	367	3.10e-08	54.7
k141_635325_40	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.7	206	535	368	3.11e-08	54.7
k141_635325_42	CARD|gb|BAB36671.1|ARO:3000832|evgA	21.1	185	216	204	3.41e-11	59.3
k141_703614_21	CARD|gb|VWQ00850.1|ARO:3003843|leuO	29.1	302	310	314	1.47e-30	116
k141_703614_30	SARG|gi|748767925|ref|WP_040019608.1|	31.8	220	266	623	1.43e-18	84.0
k141_703614_30	SARG|gi|953808775|ref|WP_058042812.1|	31.4	210	266	608	5.24e-17	79.3
k141_703614_30	SARG|gi|754608317|ref|WP_041998010.1|	32.1	212	266	612	7.10e-17	79.0
k141_703614_30	SARG|gi|664458452|ref|WP_030980047.1|	30.7	212	266	601	9.51e-17	78.6
k141_703614_30	SARG|gi|516795764|ref|WP_018105258.1|	30.7	212	266	601	1.28e-16	78.2
k141_703614_30	SARG|gi|799286378|ref|WP_045936958.1|	31.2	221	266	620	1.30e-16	78.2
k141_703614_30	SARG|gi|917127754|ref|WP_051734466.1|	31.2	221	266	620	1.30e-16	78.2
k141_703614_30	SARG|gi|926376632|ref|WP_053705806.1|	31.2	221	266	620	1.30e-16	78.2
k141_703614_30	SARG|gi|926294973|ref|WP_053631154.1|	31.2	221	266	620	1.30e-16	78.2
k141_703614_30	SARG|gi|928900436|ref|WP_053931243.1|	30.6	206	266	600	1.73e-16	77.8
k141_703614_50	CARD|gb|AAK37618.1|ARO:3005008|TxR	39.4	312	520	318	1.77e-60	201
k141_703614_52	SARG|gb|ABA71733.1|ARO:3002972|vanTG	30.7	371	373	712	2.23e-32	127
k141_703614_52	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	28.3	371	373	711	2.65e-24	103
k141_703614_52	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	27.1	340	373	366	5.99e-24	100
k141_703614_52	SARG|gi|498467693|ref|WP_010773049.1|	26.9	335	373	700	5.41e-22	96.7
k141_703614_52	SARG|FJ872411.1.gene43.p01	27.3	337	373	702	1.76e-21	95.1
k141_137044_52	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.7	126	243	247	3.09e-07	48.9
k141_137044_65	megares|MEG_2421|Drugs|beta-lactam|Class_A_betalactamases|CTX_2	39.4	94	158	107	2.26e-17	72.0
k141_137044_70	CARD|gb|BAB41874.1|ARO:3000815|mgrA	37.7	138	151	147	1.30e-20	81.3
k141_137044_78	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.6	227	230	228	2.69e-49	160
k141_137044_78	CARD|gb|AAD51348.1|ARO:3003066|smeR	40.0	225	230	229	1.56e-48	158
k141_137044_78	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	38.2	233	230	252	5.20e-43	144
k141_137044_78	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.1	231	230	232	6.04e-43	144
k141_137044_78	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.1	231	230	232	6.04e-43	144
k141_137044_78	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.2	226	230	231	7.30e-41	138
k141_137044_78	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.2	231	230	230	1.12e-39	135
k141_137044_78	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.1	229	230	232	1.18e-39	135
k141_137044_78	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	33.2	223	230	225	1.53e-38	132
k141_137044_78	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.5	231	230	231	1.79e-38	132
k141_137044_79	CARD|gb|ABD30512.1|ARO:3000839|arlS	24.5	282	432	451	2.85e-23	100
k141_137044_81	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.2	122	357	228	4.81e-12	63.9
k141_137044_81	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.0	130	357	231	1.39e-10	59.7
k141_137044_81	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	31.3	128	357	230	1.86e-10	59.3
k141_137044_81	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	35.5	107	357	225	2.37e-10	58.9
k141_137044_81	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	28.8	118	357	229	3.36e-10	58.5
k141_137044_81	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.0	97	357	219	7.34e-10	57.4
k141_137044_81	CARD|gb|AAG05188.1|ARO:3005068|ParR	33.8	74	357	235	8.83e-10	57.4
k141_137044_81	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.1	121	357	231	2.08e-09	56.2
k141_137044_81	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.7	98	357	247	2.44e-09	56.2
k141_137044_81	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	43.0	86	357	219	2.45e-09	55.8
k141_137044_83	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.3	446	1191	1197	1.26e-42	169
k141_137044_83	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	30.7	140	1191	231	7.56e-09	56.6
k141_137044_83	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	30.5	141	1191	233	1.04e-08	56.2
k141_137044_83	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.1	106	1191	228	4.32e-08	54.3
k141_137044_83	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.2	129	1191	219	3.08e-07	51.6
k141_137044_83	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	26.9	104	1191	231	1.54e-06	49.7
k141_137044_84	CARD|gb|AAG05188.1|ARO:3005068|ParR	49.4	233	235	235	6.33e-72	218
k141_137044_84	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	37.3	236	235	252	2.76e-44	148
k141_137044_84	CARD|gb|AAD51348.1|ARO:3003066|smeR	35.1	228	235	229	5.83e-44	146
k141_137044_84	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.6	228	235	228	5.40e-38	131
k141_137044_84	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.6	226	235	219	1.68e-37	129
k141_137044_84	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.6	226	235	232	3.33e-37	129
k141_137044_84	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.7	226	235	231	6.44e-37	128
k141_137044_84	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.6	227	235	220	1.49e-35	124
k141_137044_84	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.3	227	235	219	8.04e-35	122
k141_137044_84	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.3	227	235	220	8.25e-35	122
k141_137044_89	SARG|gb|AAG05187.1|ARO:3005067|ParS	34.1	440	454	428	1.58e-55	189
k141_137044_89	CARD|gb|AEX49906.1|ARO:3003583|basS	27.9	265	454	477	2.22e-17	83.2
k141_137044_89	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	30.1	226	454	357	8.59e-17	80.5
k141_137044_89	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	30.1	226	454	357	8.59e-17	80.5
k141_137044_89	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.2	246	454	364	1.71e-15	76.6
k141_137044_89	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.2	246	454	364	1.71e-15	76.6
k141_137044_89	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	26.5	211	454	380	1.10e-14	74.3
k141_137044_89	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.5	211	454	380	1.10e-14	74.3
k141_137044_89	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	40.9	93	454	359	2.29e-14	73.2
k141_137044_99	SARG|gi|736472622|ref|WP_034494292.1|	24.8	319	507	648	1.46e-17	84.7
k141_137044_99	SARG|gi|1035670474|ref|WP_064517458.1|	28.2	227	507	648	6.00e-17	82.8
k141_137044_99	SARG|gi|1035717981|ref|WP_064557480.1|	28.2	227	507	648	6.00e-17	82.8
k141_137044_99	SARG|gi|749017716|ref|WP_040076354.1|	27.6	210	507	646	1.39e-16	81.6
k141_137044_99	SARG|gi|1032819400|ref|WP_064325534.1|	29.8	188	507	646	1.39e-16	81.6
k141_137044_99	SARG|gi|779852631|ref|WP_045348970.1|	28.1	210	507	646	1.85e-16	81.3
k141_137044_99	SARG|gi|836580371|ref|WP_047737758.1|	28.1	210	507	646	1.85e-16	81.3
k141_137044_99	SARG|gi|798928072|ref|WP_045906664.1|	28.1	210	507	646	1.85e-16	81.3
k141_137044_99	SARG|gi|746222054|ref|WP_039271209.1|	28.1	210	507	646	1.85e-16	81.3
k141_137044_99	SARG|gi|1022641085|ref|WP_063404331.1|	28.1	210	507	646	1.85e-16	81.3
k141_137044_108	SARG|gi|495736522|ref|WP_008461101.1|	48.3	232	241	648	1.14e-68	221
k141_137044_108	SARG|gi|746253210|ref|WP_039301529.1|	47.8	232	241	648	4.39e-68	220
k141_137044_108	SARG|gi|1001720867|ref|WP_061274204.1|	48.1	231	241	648	8.59e-68	219
k141_137044_108	SARG|gi|639225329|ref|WP_024561799.1|	48.5	229	241	648	3.30e-67	218
k141_137044_108	SARG|gi|639218559|ref|WP_024556062.1|	48.5	229	241	648	3.30e-67	218
k141_137044_108	SARG|gi|746243059|ref|WP_039291473.1|	47.6	231	241	648	4.61e-67	217
k141_137044_108	SARG|gi|657888313|ref|WP_029592374.1|	48.5	229	241	648	6.45e-67	217
k141_137044_108	SARG|gi|803568669|ref|WP_046077412.1|	48.7	224	241	648	9.03e-67	216
k141_137044_108	SARG|gi|446110352|ref|WP_000188207.1|	48.7	224	241	648	9.03e-67	216
k141_137044_108	SARG|YP_002382193	48.7	224	241	648	9.03e-67	216
k141_137044_110	SARG|gi|969848384|ref|WP_058609247.1|	31.5	429	422	646	1.57e-31	125
k141_137044_110	SARG|gi|493171912|ref|WP_006174388.1|	31.5	429	422	646	5.27e-31	124
k141_137044_110	SARG|gi|754731641|ref|WP_042100724.1|	30.6	415	422	648	2.39e-30	122
k141_137044_110	SARG|gi|654551607|ref|WP_028019265.1|	30.5	429	422	646	5.86e-30	121
k141_137044_110	SARG|gi|779804753|ref|WP_045330664.1|	31.5	429	422	646	5.86e-30	121
k141_137044_110	SARG|gi|895905590|ref|WP_049005458.1|	30.5	429	422	646	5.86e-30	121
k141_137044_110	SARG|gi|693138751|ref|WP_032280630.1|	30.6	415	422	648	5.90e-30	121
k141_137044_110	SARG|gi|979540828|ref|WP_059340323.1|	30.4	415	422	648	5.90e-30	121
k141_137044_110	SARG|gi|446110323|ref|WP_000188178.1|	30.6	415	422	648	7.96e-30	120
k141_137044_110	SARG|gi|486363771|ref|WP_001594926.1|	30.6	415	422	648	7.96e-30	120
k141_137181_3	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	57.8	325	327	346	2.03e-135	387
k141_137181_55	SARG|gb|AAC75089.1|ARO:3003577|ugd	29.0	369	458	388	4.60e-38	141
k141_205674_17	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	28.3	198	310	314	1.17e-15	75.1
k141_840612_4	SARG|gb|APB03219.1|ARO:3003986|TaeA	39.0	513	556	648	1.49e-107	335
k141_840612_4	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	542	556	655	3.62e-62	215
k141_840612_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	542	556	655	1.34e-61	213
k141_840612_4	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	542	556	655	1.34e-61	213
k141_840612_4	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	542	556	655	1.34e-61	213
k141_840612_4	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	542	556	655	1.34e-61	213
k141_840612_4	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	542	556	655	1.34e-61	213
k141_840612_4	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	542	556	655	1.34e-61	213
k141_840612_4	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	542	556	655	1.34e-61	213
k141_840612_4	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	542	556	655	1.34e-61	213
k141_840612_24	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	41.6	632	686	633	4.44e-155	461
k141_840612_24	megares|MEG_3790|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	26.4	568	686	666	3.02e-41	159
k141_840612_24	SARG|gi|909708119|ref|WP_049951317.1|	26.8	575	686	649	2.12e-40	156
k141_840612_24	SARG|AAX35723	26.7	569	686	665	2.43e-40	156
k141_840612_24	SARG|CAL22891	26.8	575	686	668	2.50e-40	156
k141_840612_24	megares|MEG_3783|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	26.8	575	686	669	2.52e-40	156
k141_840612_24	SARG|BAG06200	26.8	575	686	669	2.52e-40	156
k141_840612_24	SARG|gi|686195077|ref|WP_031806544.1|	27.2	574	686	668	6.11e-40	155
k141_840612_24	megares|MEG_3793|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	27.0	577	686	668	8.23e-40	154
k141_840612_24	SARG|gi|486697816|ref|WP_001620256.1|	26.6	575	686	668	1.11e-39	154
k141_840612_33	SARG|gi|723111645|ref|WP_033557217.1|	35.2	213	617	648	3.47e-24	106
k141_840612_33	SARG|gi|510925114|ref|WP_016245857.1|	35.2	213	617	648	4.61e-24	105
k141_840612_33	SARG|gi|693106883|ref|WP_032260279.1|	35.2	213	617	648	6.12e-24	105
k141_840612_33	SARG|gi|735686444|ref|WP_034174061.1|	34.7	213	617	648	1.43e-23	104
k141_840612_33	SARG|gi|727407986|ref|WP_033815909.1|	34.7	213	617	648	1.43e-23	104
k141_840612_33	SARG|gi|727362702|ref|WP_033800544.1|	34.7	213	617	648	1.43e-23	104
k141_840612_33	SARG|gi|919594850|ref|WP_052892342.1|	34.3	213	617	648	1.43e-23	104
k141_840612_33	SARG|gi|446110309|ref|WP_000188164.1|	34.7	213	617	648	1.43e-23	104
k141_840612_33	SARG|gi|446110310|ref|WP_000188165.1|	34.7	213	617	648	1.43e-23	104
k141_840612_33	SARG|gi|727408814|ref|WP_033816469.1|	34.7	213	617	648	1.90e-23	103
k141_840612_45	SARG|gi|746253210|ref|WP_039301529.1|	28.4	204	422	648	4.04e-13	70.1
k141_840612_45	SARG|gi|1001720867|ref|WP_061274204.1|	28.9	204	422	648	5.36e-13	69.7
k141_840612_45	SARG|gi|1035670474|ref|WP_064517458.1|	29.7	219	422	648	9.45e-13	68.9
k141_840612_45	SARG|gi|1035717981|ref|WP_064557480.1|	29.7	219	422	648	9.45e-13	68.9
k141_840612_45	SARG|gi|495736522|ref|WP_008461101.1|	27.9	204	422	648	1.25e-12	68.6
k141_840612_45	SARG|gb|AAK76137.1|ARO:3000024|patA	27.9	208	422	564	4.71e-12	66.6
k141_840612_45	SARG|gi|736472622|ref|WP_034494292.1|	29.6	203	422	648	6.84e-12	66.2
k141_840612_45	SARG|gi|639209604|ref|WP_024547784.1|	26.5	204	422	648	1.52e-10	62.0
k141_840612_45	SARG|gi|1035706844|ref|WP_064548272.1|	28.1	203	422	648	1.52e-10	62.0
k141_840612_45	SARG|gi|654551607|ref|WP_028019265.1|	25.5	204	422	646	3.53e-10	60.8
k141_840612_58	SARG|gb|AAP82271|ARO:3004123|Burkholderia	31.3	399	355	374	8.26e-26	105
k141_25322_3	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	30.8	224	320	346	1.10e-16	78.6
k141_841499_16	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	35.7	350	362	397	1.32e-56	188
k141_841499_38	SARG|U19459.gene.p01	48.3	60	157	212	2.99e-11	58.2
k141_841499_38	SARG|M58472.1.gene1.p01	50.0	52	157	209	5.37e-10	54.7
k141_841499_38	SARG|AF418284.1.gene3.p01	48.3	60	157	210	7.49e-10	54.3
k141_841499_38	SARG|AAS89471	46.7	60	157	210	1.43e-09	53.5
k141_841499_38	SARG|AY123251.gene2.p01	46.7	60	157	210	1.43e-09	53.5
k141_841499_38	NCBI|WP_010635894.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	46.7	60	157	210	1.43e-09	53.5
k141_841499_38	NCBI|WP_071766400.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	46.7	60	157	210	1.43e-09	53.5
k141_841499_38	NCBI|WP_071593228.1|1|2|catB8|catB8|acetyltransferase|2|aminoglycoside/CHLORAMPHENICOL|aminoglycoside/PHENICOL|bifunctional_type_B-3_phenicol_O-acetyltransferase_CatB8/aminoglycoside_N-acetyltransferase_AAC(6')-Ib|AMR|multidrug	48.3	60	157	419	1.53e-09	54.3
k141_841499_38	SARG|FJ460181.2.gene2.p01	46.7	60	157	210	1.97e-09	53.1
k141_841499_38	SARG|AF139725.gene.p01	51.0	51	157	214	2.04e-09	53.1
k141_841499_87	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	39.0	210	291	307	1.33e-45	155
k141_841499_87	SARG|gi|488068784|ref|WP_002140181.1|	39.0	210	291	309	7.67e-45	153
k141_841499_87	SARG|gi|488130770|ref|WP_002201978.1|	39.0	210	291	309	1.08e-44	152
k141_841499_87	SARG|gi|507023808|ref|WP_016095885.1|	39.0	210	291	309	1.08e-44	152
k141_841499_87	SARG|gi|507055561|ref|WP_016126482.1|	38.6	210	291	309	1.51e-44	152
k141_841499_87	SARG|gi|488053456|ref|WP_002124853.1|	38.6	210	291	309	2.13e-44	152
k141_841499_87	SARG|gi|447057509|ref|WP_001134765.1|	36.2	246	291	309	2.13e-44	152
k141_841499_87	SARG|gi|488067981|ref|WP_002139378.1|	38.6	210	291	309	2.99e-44	151
k141_841499_87	SARG|gi|487936534|ref|WP_002010000.1|	38.6	210	291	309	2.99e-44	151
k141_841499_87	SARG|gi|447057510|ref|WP_001134766.1|	39.0	210	291	309	2.99e-44	151
k141_841499_88	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.8	258	796	1197	4.86e-28	120
k141_841499_111	CARD|gb|BAE77933.1|ARO:3000518|CRP	31.9	188	212	210	1.85e-26	100
k141_1045684_26	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	33.9	218	350	346	6.45e-19	85.5
k141_479665_8	SARG|gi|763064330|ref|WP_043946082.1|	26.0	327	395	385	9.53e-17	80.1
k141_479665_8	SARG|gi|755835325|ref|WP_042591034.1|	26.0	327	395	385	1.72e-16	79.3
k141_479665_8	SARG|gi|502972697|ref|WP_013207673.1|	25.7	327	395	385	3.11e-16	78.6
k141_479665_8	SARG|YP_002256705	26.3	331	395	385	5.61e-16	77.8
k141_479665_8	SARG|gi|746541139|ref|WP_039573465.1|	26.3	331	395	385	5.61e-16	77.8
k141_479665_8	SARG|gi|746517374|ref|WP_039553500.1|	26.3	331	395	385	5.61e-16	77.8
k141_479665_8	SARG|gi|942503284|ref|WP_055335444.1|	26.3	331	395	385	5.61e-16	77.8
k141_479665_8	SARG|gi|942479276|ref|WP_055325699.1|	26.3	331	395	385	5.61e-16	77.8
k141_479665_8	SARG|ZP_00946143	26.3	331	395	385	5.61e-16	77.8
k141_479665_8	SARG|gi|504432599|ref|WP_014619701.1|	26.3	331	395	385	7.53e-16	77.4
k141_479665_9	CARD|gb|AAC75137.1|ARO:3000794|mdtC	29.4	1010	1075	1025	5.75e-137	438
k141_479665_9	SARG|gb|BAE06006.1|ARO:3003705|mexN	30.0	1027	1075	1036	8.58e-129	417
k141_479665_9	SARG|gb|AAG05914|ARO:3004075|MuxC	30.5	1027	1075	1036	8.85e-124	403
k141_479665_9	SARG|gb|AAG05915.1|ARO:3004074|MuxB	27.8	1018	1075	1043	3.60e-116	383
k141_479665_9	CARD|gb|AAG07594.1|ARO:3000808|MexI	27.0	1020	1075	1029	1.37e-114	378
k141_479665_9	CARD|gb|AAC75136.1|ARO:3000793|mdtB	26.9	1029	1075	1040	1.70e-114	378
k141_479665_9	SARG|gb|AAL19305.1|ARO:3000790|mdsB	28.6	1047	1075	1055	8.15e-113	374
k141_479665_9	SARG|YP_001187672	28.9	1059	1075	1059	3.12e-111	370
k141_479665_9	SARG|CAY51926	27.3	1015	1075	1008	3.06e-110	366
k141_479665_9	SARG|gi|764528042|ref|WP_044407471.1|	28.1	1084	1075	1062	6.10e-110	366
k141_388920_3	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	20.9	901	876	1107	6.57e-12	68.6
k141_388920_3	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	20.9	901	876	1107	6.57e-12	68.6
k141_388920_10	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.8	115	145	228	7.21e-15	67.8
k141_388920_10	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.3	114	145	219	3.37e-13	63.2
k141_388920_10	CARD|gb|BAB36671.1|ARO:3000832|evgA	26.1	115	145	204	3.88e-12	60.1
k141_388920_10	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.6	104	145	232	2.72e-11	58.2
k141_388920_10	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.3	120	145	223	6.34e-10	54.3
k141_388920_10	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.1	106	145	231	2.44e-09	52.8
k141_388920_10	CARD|gb|AAG05188.1|ARO:3005068|ParR	26.3	114	145	235	2.10e-07	47.4
k141_388920_10	SARG|ZP_02848503	28.1	114	145	221	2.67e-07	47.0
k141_388920_25	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.0	118	2254	231	3.43e-15	76.3
k141_388920_25	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.8	118	2254	232	8.67e-15	75.1
k141_388920_25	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.6	114	2254	228	1.47e-14	74.3
k141_388920_25	CARD|gb|ADM92605.1|ARO:3000553|adeR	25.8	120	2254	247	5.64e-13	70.1
k141_388920_25	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.7	113	2254	1197	4.36e-10	64.3
k141_388920_28	CARD|gb|AAG05188.1|ARO:3005068|ParR	36.4	118	122	235	9.25e-24	90.5
k141_388920_28	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.2	116	122	228	2.24e-23	89.4
k141_388920_28	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.7	116	122	219	1.21e-20	82.0
k141_388920_28	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.2	113	122	229	7.88e-20	80.1
k141_388920_28	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.1	114	122	231	6.17e-19	77.8
k141_388920_28	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.5	112	122	230	2.33e-18	76.3
k141_388920_28	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.3	114	122	231	2.37e-18	76.3
k141_388920_28	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	35.4	113	122	231	2.37e-18	76.3
k141_388920_28	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.3	114	122	231	3.32e-18	75.9
k141_388920_28	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.3	114	122	231	4.65e-18	75.5
k141_388920_29	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.7	115	134	219	1.25e-14	66.6
k141_388920_29	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.7	115	134	219	1.25e-14	66.6
k141_388920_29	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.7	115	134	220	1.26e-14	66.6
k141_388920_29	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.7	115	134	220	3.42e-14	65.5
k141_388920_32	NCBI|AAN29871.1|1|1|bepC|bepC||1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_outer_membrane_subunit_BepC|AMR|efflux	26.4	386	624	456	4.12e-24	104
k141_388920_32	SARG|CP000675.2.gene810.p01	18.9	412	624	455	2.30e-15	77.8
k141_388920_32	SARG|gi|1005410900|ref|WP_061640132.1|	18.4	412	624	455	2.23e-14	74.7
k141_388920_32	SARG|gi|754878317|ref|WP_042238014.1|	18.4	412	624	455	3.92e-14	73.9
k141_388920_32	SARG|gi|652975683|ref|WP_027228387.1|	18.2	412	624	455	6.90e-14	73.2
k141_388920_32	SARG|gi|504656419|ref|WP_014843521.1|	18.3	410	624	455	1.21e-13	72.4
k141_388920_32	SARG|gi|515614850|ref|WP_017047450.1|	23.3	438	624	435	1.98e-13	71.6
k141_388920_32	SARG|gi|499248896|ref|WP_010946436.1|	18.2	412	624	455	2.14e-13	71.6
k141_388920_32	SARG|gi|652967291|ref|WP_027220262.1|	18.2	412	624	455	2.14e-13	71.6
k141_388920_32	SARG|gi|515613899|ref|WP_017046499.1|	23.3	438	624	435	2.63e-13	71.2
k141_910129_9	CARD|gb|TKW44661.1|ARO:3005040|YajC	46.7	105	108	112	2.77e-23	85.5
k141_910129_12	CARD|gb|AAC75135.2|ARO:3000792|mdtA	29.7	390	433	415	9.81e-41	149
k141_910129_12	SARG|gb|BAE06005.1|ARO:3003704|mexM	32.0	331	433	385	2.80e-39	144
k141_910129_12	SARG|gi|491209910|ref|WP_005068241.1|	27.2	379	433	406	7.82e-38	140
k141_910129_12	SARG|gi|691070849|ref|WP_032012412.1|	27.2	379	433	406	7.82e-38	140
k141_910129_12	SARG|gi|691139985|ref|WP_032053373.1|	28.2	379	433	406	1.08e-37	140
k141_910129_12	SARG|gi|748187801|ref|WP_039758925.1|	27.2	379	433	406	1.08e-37	140
k141_910129_12	SARG|gi|727726402|ref|WP_033847639.1|	27.2	379	433	406	1.08e-37	140
k141_910129_12	SARG|gi|515955949|ref|WP_017386532.1|	27.2	379	433	406	1.50e-37	140
k141_910129_12	NCBI|CAK15125.1|1|1|mexE|mexE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_MexE|AMR|efflux	27.2	345	433	413	1.21e-31	124
k141_910129_12	SARG|EU408352.1.gene3.p01	27.1	310	433	398	6.69e-28	113
k141_910129_13	SARG|gb|AAG05915.1|ARO:3004074|MuxB	45.0	1024	1029	1043	1.22e-283	818
k141_910129_13	CARD|gb|AAC75137.1|ARO:3000794|mdtC	44.4	1017	1029	1025	7.83e-280	808
k141_910129_13	SARG|gb|AAG05914|ARO:3004075|MuxC	44.0	1020	1029	1036	9.09e-276	798
k141_910129_13	SARG|gb|BAE06006.1|ARO:3003705|mexN	44.5	1019	1029	1036	3.73e-269	781
k141_910129_13	CARD|gb|AAC75136.1|ARO:3000793|mdtB	42.9	1017	1029	1040	8.47e-269	780
k141_910129_13	SARG|CAY51926	29.5	1019	1029	1008	1.04e-143	454
k141_910129_13	SARG|YP_350221	29.6	1019	1029	1009	1.49e-143	454
k141_910129_13	SARG|YP_792720	29.0	1018	1029	1018	3.24e-137	437
k141_910129_13	SARG|AAG07763	28.9	1018	1029	1018	1.23e-136	436
k141_910129_13	SARG|YP_001350280	28.6	1018	1029	1018	9.09e-136	434
k141_910129_20	SARG|gi|951144970|ref|WP_057625744.1|	48.7	277	308	294	1.31e-91	273
k141_910129_20	SARG|gi|910885777|ref|WP_050131597.1|	48.7	277	308	294	1.31e-91	273
k141_910129_20	SARG|gi|818397829|ref|WP_046694984.1|	48.7	277	308	294	1.31e-91	273
k141_910129_20	SARG|gi|915697058|ref|WP_050869942.1|	48.7	277	308	294	1.85e-91	273
k141_910129_20	SARG|gi|912862495|ref|WP_050298167.1|	48.7	277	308	294	1.85e-91	273
k141_910129_20	SARG|gi|910771266|ref|WP_050078031.1|	48.7	275	308	294	2.63e-91	272
k141_910129_20	SARG|gi|912859645|ref|WP_050296155.1|	52.5	257	308	293	3.60e-91	272
k141_910129_20	SARG|gi|912451930|ref|WP_050163074.1|	48.7	277	308	294	3.72e-91	272
k141_910129_20	SARG|CAJ43422	48.7	277	308	291	4.78e-91	271
k141_910129_20	SARG|gi|915865859|ref|WP_050916711.1|	50.8	256	308	294	5.27e-91	271
k141_910129_32	CARD|gb|AAK37618.1|ARO:3005008|TxR	38.2	322	474	318	2.18e-61	202
k141_910129_32	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	34.7	118	474	225	7.14e-15	72.8
k141_910129_32	CARD|gb|AAC73788.1|ARO:3003841|kdpE	34.7	118	474	225	7.14e-15	72.8
k141_910129_32	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.2	125	474	228	6.39e-11	61.2
k141_910129_32	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	30.2	116	474	231	1.78e-09	57.0
k141_910129_32	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	28.4	116	474	231	3.48e-08	53.1
k141_910129_46	SARG|gb|WP_063864750.1|ARO:3006999|SST-1	25.5	330	579	378	1.23e-17	84.0
k141_910129_46	SARG|KF992029.1.gene1.p01	26.3	270	579	381	1.69e-17	83.6
k141_910129_46	SARG|AAQ90024	25.0	388	579	374	5.11e-17	82.0
k141_910129_46	SARG|gi|896175180|ref|WP_049188167.1|	24.7	392	579	378	9.46e-17	81.3
k141_910129_46	NCBI|WP_117581582.1|1|1|blaACT-150|blaACT|hydrolase|2|CEPHALOSPORIN|beta-lactam|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-150|AMR|beta-lactam	25.6	270	579	381	1.30e-16	80.9
k141_910129_46	SARG|AY524276.3.gene1.p3	24.7	392	579	378	1.69e-16	80.5
k141_910129_46	SARG|AAK15701	24.7	392	579	378	1.69e-16	80.5
k141_910129_46	SARG|AB008454.1.gene1.p01	24.5	392	579	378	2.26e-16	80.1
k141_910129_46	SARG|gi|896236319|ref|WP_049234464.1|	24.7	392	579	378	3.03e-16	79.7
k141_910129_46	SARG|ABC33904	24.7	392	579	378	3.03e-16	79.7
k141_910129_49	CARD|gb|AFK13828.1|ARO:3000823|ramA	39.6	91	302	124	2.91e-17	75.5
k141_910129_49	megares|MEG_7070|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETD_1	42.6	94	302	138	4.12e-17	75.5
k141_910129_84	SARG|gi|501336065|ref|WP_012367700.1|	27.1	343	387	369	1.06e-19	88.6
k141_910129_84	SARG|gi|896239619|ref|WP_049236948.1|	27.1	343	387	369	1.95e-19	87.8
k141_910129_84	SARG|gi|810389049|ref|WP_046335163.1|	27.1	343	387	369	1.95e-19	87.8
k141_910129_84	SARG|CP004022.1.gene757.p01	27.1	343	387	369	1.95e-19	87.8
k141_910129_84	SARG|gi|490367950|ref|WP_004247613.1|	27.1	343	387	369	1.95e-19	87.8
k141_910129_84	SARG|gi|739100685|ref|WP_036971354.1|	27.1	343	387	369	1.95e-19	87.8
k141_910129_84	SARG|gi|516438819|ref|WP_017827731.1|	27.1	343	387	369	1.95e-19	87.8
k141_910129_84	CARD|gb|AAG03546.1|ARO:3003679|TriA	26.6	301	387	383	2.44e-18	84.7
k141_910129_84	CARD|gb|AAL14439.1|ARO:3000774|adeA	25.7	315	387	396	3.10e-16	78.6
k141_910129_84	SARG|gi|690979835|ref|WP_031953602.1|	33.9	174	387	446	3.05e-13	69.7
k141_910129_85	SARG|YP_001187672	25.6	1052	1099	1059	1.84e-63	233
k141_910129_85	SARG|gb|BAE06006.1|ARO:3003705|mexN	26.3	1086	1099	1036	5.19e-62	229
k141_910129_85	SARG|gi|655279967|ref|WP_028689378.1|	24.9	1047	1099	1059	6.03e-61	226
k141_910129_85	SARG|gi|489327637|ref|WP_003234928.1|	24.6	1045	1099	1059	6.03e-61	226
k141_910129_85	SARG|YP_607927	24.8	1044	1099	1059	8.04e-61	225
k141_910129_85	SARG|gi|544849761|ref|WP_021264856.1|	24.8	1065	1099	1062	8.18e-61	225
k141_910129_85	SARG|gi|550043906|ref|WP_022580472.1|	24.8	1065	1099	1062	8.18e-61	225
k141_910129_85	SARG|gi|844727272|ref|WP_047925316.1|	24.7	1065	1099	1062	1.09e-60	225
k141_910129_85	SARG|gi|489252358|ref|WP_003160388.1|	24.7	1065	1099	1062	1.45e-60	224
k141_910129_85	SARG|gi|757686578|ref|WP_042917070.1|	24.7	1065	1099	1062	1.45e-60	224
k141_910129_93	SARG|gb|WP_104671188.1|ARO:3003948|efrA	26.1	241	256	575	2.55e-16	77.0
k141_910129_93	SARG|gb|WP_082039181.1|ARO:3007028|salD	25.7	202	256	544	8.75e-12	63.5
k141_910129_93	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.9	197	256	655	8.33e-09	54.7
k141_910129_93	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.9	197	256	655	8.33e-09	54.7
k141_910129_93	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.9	197	256	655	8.33e-09	54.7
k141_910129_93	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.9	197	256	655	8.33e-09	54.7
k141_910129_93	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.9	197	256	655	8.33e-09	54.7
k141_910129_93	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.9	197	256	655	8.33e-09	54.7
k141_910129_93	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.9	197	256	655	8.33e-09	54.7
k141_910129_93	SARG|gb|AKA86814|ARO:3003746|optrA	23.9	197	256	655	8.33e-09	54.7
k141_910129_94	SARG|gb|XP_753111.1|ARO:3003942|abcA	26.3	205	294	1452	1.16e-08	55.1
k141_910129_121	CARD|gb|WKR28567.1|ARO:3007678|IreK	33.8	260	732	718	1.25e-30	127
k141_910129_122	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.0	86	139	231	3.36e-07	46.6
k141_910129_122	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.1	84	139	232	1.19e-06	45.1
k141_910129_123	CARD|gb|AAK37618.1|ARO:3005008|TxR	31.0	332	523	318	7.32e-37	137
k141_910129_127	SARG|gb|AAC74000.1|ARO:3003950|msbA	40.5	568	579	582	2.59e-143	426
k141_910129_127	SARG|gi|860594225|ref|WP_048475168.1|	31.6	572	579	620	8.13e-82	267
k141_910129_127	SARG|gi|926351744|ref|WP_053683383.1|	31.3	572	579	648	1.18e-79	262
k141_910129_127	SARG|gi|1045390184|ref|WP_065479071.1|	30.3	574	579	605	1.24e-79	261
k141_910129_127	SARG|gi|664317010|ref|WP_030845774.1|	30.8	574	579	605	1.73e-79	261
k141_910129_127	SARG|gi|663286402|ref|WP_030292859.1|	30.8	574	579	605	1.73e-79	261
k141_910129_127	SARG|gi|663342223|ref|WP_030341347.1|	30.8	574	579	605	1.73e-79	261
k141_910129_127	SARG|gi|759527374|ref|WP_043247487.1|	30.8	574	579	605	1.73e-79	261
k141_910129_127	SARG|gi|664194237|ref|WP_030727956.1|	30.8	574	579	605	1.73e-79	261
k141_910129_127	SARG|gi|663330365|ref|WP_030329892.1|	30.8	574	579	607	3.54e-79	260
k141_910129_136	CARD|gb|AAK37618.1|ARO:3005008|TxR	41.4	244	506	318	1.97e-52	179
k141_592650_2	CARD|gb|BAB36671.1|ARO:3000832|evgA	24.8	202	215	204	5.36e-16	72.4
k141_592650_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	28.6	119	215	228	4.05e-10	56.6
k141_592650_2	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.8	131	215	235	3.19e-06	45.4
k141_1070245_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.7	115	131	231	1.34e-12	61.2
k141_1070245_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.8	116	131	232	9.65e-12	58.9
k141_1070245_3	CARD|gb|AAD51348.1|ARO:3003066|smeR	31.5	127	131	229	3.45e-11	57.4
k141_1070245_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.7	120	131	228	8.72e-10	53.5
k141_1070245_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.5	120	131	219	1.47e-08	50.1
k141_1070245_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.5	120	131	219	1.47e-08	50.1
k141_1070245_3	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.5	120	131	220	1.48e-08	50.1
k141_1070245_3	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.5	120	131	220	3.88e-08	48.9
k141_1070245_3	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	120	131	220	1.75e-06	44.3
k141_1070245_4	CARD|gb|AAD51348.1|ARO:3003066|smeR	31.4	121	548	229	3.53e-18	82.8
k141_1070245_4	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	34.3	102	548	225	1.24e-11	63.5
k141_1070245_4	CARD|gb|AAC73788.1|ARO:3003841|kdpE	34.3	102	548	225	1.24e-11	63.5
k141_1070245_6	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	41.9	236	288	703	1.11e-51	179
k141_526786_7	SARG|YP_002181880	29.7	145	411	536	4.34e-13	69.7
k141_526786_7	SARG|NP_733568	29.7	145	411	536	1.36e-12	68.2
k141_526786_7	SARG|YP_002203876	27.6	145	411	539	4.25e-12	66.6
k141_526786_7	SARG|YP_002193132	28.3	145	411	537	5.63e-12	66.2
k141_526786_7	SARG|NP_826974	26.9	145	411	540	1.76e-11	64.7
k141_526786_7	SARG|YP_002188856	28.3	145	411	537	4.11e-11	63.5
k141_526786_7	SARG|gi|896469661|ref|WP_049389686.1|	23.5	136	411	387	8.42e-07	49.7
k141_526786_7	SARG|gi|695601926|ref|WP_032604580.1|	22.8	136	411	381	2.58e-06	48.1
k141_526786_7	SARG|gi|488430666|ref|WP_002500051.1|	22.8	136	411	387	2.61e-06	48.1
k141_526786_7	SARG|gi|488407009|ref|WP_002476394.1|	22.8	136	411	387	2.61e-06	48.1
k141_526786_8	SARG|gb|AAP82271|ARO:3004123|Burkholderia	36.1	202	333	374	2.63e-19	86.7
k141_526786_15	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	35.6	222	288	293	1.94e-39	138
k141_526786_15	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	37.0	227	288	307	3.77e-39	138
k141_526786_15	SARG|gi|446026113|ref|WP_000103968.1|	35.2	227	288	306	2.12e-37	133
k141_526786_15	SARG|gi|507044560|ref|WP_016115614.1|	34.8	227	288	306	1.15e-36	131
k141_526786_15	SARG|gi|664458452|ref|WP_030980047.1|	31.8	217	288	601	6.30e-16	76.6
k141_526786_15	SARG|gi|1033217078|gb|OAR27197.1|	32.6	215	288	601	8.49e-16	76.3
k141_526786_15	SARG|gi|695842130|ref|WP_032755430.1|	30.7	215	288	603	8.50e-16	76.3
k141_526786_15	SARG|gi|505420018|ref|WP_015607120.1|	30.7	215	288	603	8.50e-16	76.3
k141_526786_15	SARG|gi|748767925|ref|WP_040019608.1|	30.8	214	288	623	8.63e-16	76.3
k141_526786_15	SARG|gi|1011969930|ref|WP_062776015.1|	32.5	212	288	601	1.54e-15	75.5
k141_526786_18	SARG|ZP_04577926	64.6	277	278	276	1.78e-121	347
k141_526786_18	SARG|YP_294981	60.5	291	278	293	3.11e-114	329
k141_526786_18	SARG|ZP_03265942	61.5	278	278	278	4.34e-113	326
k141_526786_18	SARG|YP_560128	60.4	278	278	278	1.76e-112	324
k141_526786_18	SARG|YP_584847	60.8	291	278	293	5.90e-112	323
k141_526786_18	SARG|YP_002006347	59.5	291	278	293	1.19e-111	323
k141_526786_18	SARG|YP_001896735	60.1	278	278	278	4.10e-111	321
k141_526786_18	SARG|YP_970399	61.4	277	278	274	4.13e-110	318
k141_526786_18	SARG|YP_002260505	59.8	291	278	293	5.55e-110	318
k141_526786_18	SARG|ABM94007	59.3	285	278	285	8.51e-110	318
k141_526786_23	SARG|gb|AAG08359.1|ARO:3003682|OpmH	34.3	426	439	482	4.10e-60	202
k141_526786_23	SARG|gi|764440891|ref|WP_044366757.1|	32.2	422	439	439	1.28e-57	194
k141_526786_23	SARG|gi|495352880|ref|WP_008077604.1|	31.9	436	439	436	6.41e-57	192
k141_526786_23	SARG|gi|692125167|ref|WP_032081234.1|	32.0	422	439	439	9.61e-57	192
k141_526786_23	SARG|gi|652975683|ref|WP_027228387.1|	32.2	441	439	455	2.01e-55	189
k141_526786_23	SARG|CP000675.2.gene810.p01	32.1	445	439	455	2.01e-55	189
k141_526786_23	SARG|gi|966433657|ref|WP_058474090.1|	31.4	449	439	455	2.01e-55	189
k141_526786_23	SARG|gi|763321415|ref|WP_044179865.1|	32.2	432	439	481	3.50e-55	189
k141_526786_23	SARG|gi|654934447|ref|WP_028384763.1|	31.4	449	439	455	7.65e-55	187
k141_526786_23	SARG|gi|941039122|ref|WP_055051514.1|	31.1	437	439	438	1.03e-54	187
k141_458290_35	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.8	125	319	231	2.15e-06	47.0
k141_458290_76	SARG|AUI09862.1	37.9	280	287	287	1.45e-55	180
k141_458290_76	SARG|AJ459418.gene.p01	38.6	259	287	263	2.57e-53	173
k141_458290_76	SARG|gi|970263436|ref|WP_058647620.1|	38.6	259	287	263	3.63e-53	173
k141_458290_76	SARG|gi|487670925|ref|WP_001756235.1|	34.6	260	287	271	7.21e-45	152
k141_458290_76	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	34.2	260	287	271	1.01e-44	151
k141_458290_76	SARG|gi|920213921|ref|WP_052970363.1|	34.6	260	287	271	1.43e-44	151
k141_458290_76	SARG|gi|979830602|ref|WP_059342829.1|	34.2	260	287	271	2.01e-44	150
k141_458290_76	SARG|DQ464881.1.gene2.p01	34.2	260	287	271	2.01e-44	150
k141_458290_76	SARG|gi|486033774|ref|WP_001505252.1|	34.2	260	287	271	2.01e-44	150
k141_458290_76	SARG|gi|1028099083|ref|WP_063855540.1|	34.2	260	287	271	2.83e-44	150
k141_458290_94	SARG|gb|AAA26793|ARO:3003748|oleC	36.8	310	316	325	5.53e-54	178
k141_458290_94	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	37.0	308	316	325	7.79e-54	177
k141_458290_94	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	33.1	311	316	343	2.08e-51	172
k141_458290_94	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	33.1	317	316	351	3.70e-40	142
k141_458290_94	SARG|gb|AAR96051.1|ARO:3002894|otrC	33.1	317	316	351	5.18e-40	142
k141_458290_94	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	37.0	200	316	293	8.02e-39	137
k141_458290_94	SARG|gi|542061059|gb|ERI11611.1|	35.9	223	316	316	1.02e-37	135
k141_458290_94	SARG|gi|447195835|ref|WP_001273091.1|	36.9	214	316	306	2.24e-37	134
k141_458290_94	SARG|gi|447195836|ref|WP_001273092.1|	36.4	214	316	306	6.14e-37	133
k141_458290_94	SARG|gi|500194536|ref|WP_011867743.1|	35.9	223	316	306	8.59e-37	132
k141_186240_17	CARD|gb|AAG05188.1|ARO:3005068|ParR	36.3	102	256	235	2.98e-10	57.8
k141_186240_17	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.7	148	256	228	8.30e-06	44.7
k141_186240_33	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	28.6	245	393	574	4.94e-20	90.9
k141_186240_33	SARG|gb|AAK76137.1|ARO:3000024|patA	28.6	210	393	564	1.26e-16	80.5
k141_186240_35	SARG|gi|895865878|ref|WP_048974758.1|	35.7	210	366	646	6.69e-28	114
k141_186240_35	SARG|gi|817122037|ref|WP_046494699.1|	31.3	227	366	613	4.97e-20	90.5
k141_186240_47	megares|MEG_2997|Drugs|Fosfomycin|Fosfomycin_thiol_transferases|FOSA_1	38.9	72	203	191	1.23e-07	48.9
k141_186240_62	NCBI|WP_018211347.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	35.7	252	318	345	7.12e-45	155
k141_186240_62	SARG|gi|1028100561|ref|WP_063856696.1|	37.0	265	318	349	1.53e-44	154
k141_186240_62	SARG|DQ212986.1.gene8.p01	35.8	265	318	349	2.28e-43	151
k141_186240_62	SARG|gi|405945042|pdb|4FU0|A	35.8	265	318	357	2.73e-43	151
k141_186240_62	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	36.5	255	318	366	3.32e-43	151
k141_186240_62	SARG|AAD42184	32.9	337	318	343	3.92e-43	150
k141_186240_62	SARG|gi|765411304|ref|WP_044689514.1|	35.8	265	318	349	4.48e-43	150
k141_186240_62	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_5	34.5	252	318	359	1.10e-42	149
k141_186240_62	SARG|gi|752682279|ref|WP_041330231.1|	35.8	265	318	349	1.23e-42	149
k141_186240_62	SARG|AAF71281	35.5	265	318	349	1.23e-42	149
k141_186240_68	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	32.6	460	460	481	1.21e-50	177
k141_186240_68	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	31.8	456	460	451	1.29e-50	177
k141_186240_68	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	32.5	456	460	451	1.30e-49	174
k141_186240_70	ResF|penA_1_AF515059_1	44.3	558	589	581	4.09e-156	459
k141_186240_70	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	26.7	514	589	674	9.53e-23	101
k141_186240_70	SARG|gb|AQX82857.1|ARO:3004185|mecD	26.7	524	589	678	1.69e-22	100
k141_186240_70	SARG|gb|BAI83385.1|ARO:3003440|mecB	26.5	514	589	674	3.92e-22	99.8
k141_186240_70	SARG|gi|2791908|emb|CAA73538.1|	23.6	539	589	666	2.65e-20	94.0
k141_186240_70	megares|MEG_3792|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	23.4	543	589	666	4.65e-20	93.2
k141_186240_70	SARG|AAX35723	23.2	538	589	665	2.51e-19	90.9
k141_186240_70	megares|MEG_3790|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	22.9	538	589	666	2.51e-19	90.9
k141_186240_70	SARG|CAA70425	22.7	542	589	666	3.33e-19	90.5
k141_186240_70	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	25.9	513	589	665	5.83e-19	89.7
k141_186240_89	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.4	81	1607	204	1.93e-07	52.4
k141_186240_107	CARD|gb|AAC75137.1|ARO:3000794|mdtC	30.2	1027	1069	1025	2.84e-144	457
k141_186240_107	SARG|gb|AAG05914|ARO:3004075|MuxC	29.9	1035	1069	1036	5.59e-125	406
k141_186240_107	SARG|gb|BAE06006.1|ARO:3003705|mexN	29.0	1025	1069	1036	5.59e-125	406
k141_186240_107	CARD|gb|AAG07594.1|ARO:3000808|MexI	27.1	1013	1069	1029	9.35e-121	395
k141_186240_107	SARG|gb|AAL19305.1|ARO:3000790|mdsB	28.6	1043	1069	1055	3.96e-115	380
k141_186240_107	SARG|gb|CAH14033.1|ARO:3004100|LpeB	28.4	1025	1069	1014	1.21e-112	372
k141_186240_107	SARG|gi|950546578|ref|WP_057422848.1|	27.6	1064	1069	1063	1.13e-111	371
k141_186240_107	SARG|gi|514421161|ref|WP_016568324.1|	27.8	1060	1069	1063	1.13e-111	371
k141_186240_107	SARG|gi|940417834|ref|WP_055007142.1|	27.6	1064	1069	1063	1.13e-111	371
k141_186240_107	SARG|gi|489512421|ref|WP_003417270.1|	28.1	1062	1069	1063	1.13e-111	371
k141_186240_108	SARG|gi|763064330|ref|WP_043946082.1|	26.0	319	415	385	5.76e-18	84.0
k141_186240_108	SARG|gi|504432599|ref|WP_014619701.1|	26.0	319	415	385	5.76e-18	84.0
k141_186240_108	SARG|YP_002256705	26.0	319	415	385	7.76e-18	83.6
k141_186240_108	SARG|gi|746541139|ref|WP_039573465.1|	26.0	319	415	385	7.76e-18	83.6
k141_186240_108	SARG|gi|755835325|ref|WP_042591034.1|	26.0	319	415	385	7.76e-18	83.6
k141_186240_108	SARG|gi|942479276|ref|WP_055325699.1|	26.0	319	415	385	7.76e-18	83.6
k141_186240_108	SARG|gi|502972697|ref|WP_013207673.1|	25.7	319	415	385	1.89e-17	82.4
k141_186240_108	SARG|gi|746517374|ref|WP_039553500.1|	25.7	319	415	385	2.54e-17	82.0
k141_186240_108	SARG|gi|942503284|ref|WP_055335444.1|	25.7	319	415	385	2.54e-17	82.0
k141_186240_108	SARG|ZP_00946143	25.7	319	415	385	2.54e-17	82.0
k141_186240_125	CARD|gb|AAG06465.1|ARO:3005063|cprR	40.4	228	226	223	1.65e-45	150
k141_186240_125	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.1	225	226	219	3.29e-41	139
k141_186240_125	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	37.7	220	226	231	1.51e-35	124
k141_186240_125	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	35.5	220	226	233	1.24e-34	122
k141_186240_125	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.5	224	226	219	1.35e-33	119
k141_186240_125	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.5	224	226	219	1.89e-33	119
k141_186240_125	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.5	224	226	220	1.94e-33	119
k141_186240_125	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.5	224	226	220	5.42e-33	117
k141_186240_125	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.1	224	226	220	6.47e-31	112
k141_186240_125	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.1	240	226	235	9.76e-25	96.7
k141_186240_130	CARD|gb|AAC75429.1|ARO:3000833|evgS	33.8	237	1968	1197	6.70e-28	122
k141_186240_166	SARG|gb|CEJ95855.1|ARO:3004595|erm45	28.0	182	257	245	6.99e-19	82.0
k141_186240_166	NCBI|WP_311033296.1|1|1|erm(55)|erm(55)|target_modification|2|CLARITHROMYCIN|MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(55)|AMR|macrolide	28.9	187	257	270	1.48e-14	70.5
k141_186240_166	SARG|AY234334.1.orf0.gene.p01	22.8	237	257	281	7.93e-14	68.6
k141_186240_166	SARG|P45438	24.7	227	257	287	7.34e-13	65.9
k141_186240_166	SARG|M29832.gene.p01	24.2	231	257	287	2.91e-11	61.2
k141_186240_166	SARG|Q04720	24.9	189	257	287	9.84e-11	59.7
k141_186240_169	CARD|gb|AIA35096.1|ARO:3005059|LptD	25.7	746	776	782	9.93e-61	218
k141_934653_11	CARD|gb|CAA79966.1|ARO:3003665|NmcR	32.2	289	299	295	2.59e-34	125
k141_934653_11	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	31.0	281	299	291	9.09e-34	124
k141_934653_24	SARG|gi|552942232|ref|WP_023043160.1|	33.2	208	315	323	2.76e-21	91.3
k141_934653_24	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	28.9	294	315	314	8.73e-21	89.7
k141_934653_24	SARG|AY082011.1.gene6.p01	32.7	208	315	323	1.84e-20	89.0
k141_934653_24	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	32.7	205	315	323	2.05e-18	83.2
k141_934653_56	SARG|gb|AAC74000.1|ARO:3003950|msbA	34.4	588	618	582	4.07e-95	302
k141_934653_56	SARG|gi|926400371|ref|WP_053728483.1|	31.9	589	618	603	1.61e-86	280
k141_934653_56	SARG|gi|947982677|ref|WP_056642336.1|	31.5	590	618	626	2.40e-82	270
k141_934653_56	SARG|gi|817122037|ref|WP_046494699.1|	31.5	585	618	613	2.48e-82	270
k141_934653_56	SARG|gi|944009777|ref|WP_055601444.1|	31.9	590	618	628	6.85e-82	269
k141_934653_56	SARG|gi|639892676|ref|WP_024755698.1|	31.4	590	618	631	7.34e-82	269
k141_934653_56	SARG|gi|664304639|ref|WP_030834011.1|	32.5	600	618	614	1.36e-81	268
k141_934653_56	SARG|gi|772774655|ref|WP_045322518.1|	31.8	588	618	620	4.25e-81	266
k141_934653_56	SARG|gi|1033151784|ref|WP_064457526.1|	32.5	600	618	614	7.23e-81	266
k141_934653_56	SARG|gi|944152509|ref|WP_055644808.1|	31.2	590	618	616	7.57e-81	266
k141_934653_60	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	36.0	236	314	307	3.34e-35	128
k141_934653_60	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	30.2	298	314	293	4.07e-29	112
k141_911141_13	CARD|gb|ALH22601.1|ARO:3000620|adeL	32.9	283	297	337	2.16e-46	158
k141_911141_24	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.5	154	622	1197	8.78e-12	67.4
k141_911141_64	SARG|gi|488374619|ref|WP_002444004.1|	24.4	418	455	452	1.29e-21	95.9
k141_911141_78	SARG|gb|AAG06942.1|ARO:3002985|arnA	32.6	291	322	662	2.37e-35	134
k141_911141_78	SARG|B7LM76	27.1	321	322	660	6.28e-31	121
k141_911141_78	SARG|gi|507086291|ref|WP_016157032.1|	27.4	325	322	660	1.16e-30	120
k141_911141_78	SARG|gi|765458296|ref|WP_044714032.1|	27.4	325	322	660	1.16e-30	120
k141_911141_78	SARG|gi|851917461|ref|WP_048217311.1|	27.1	325	322	660	2.14e-30	120
k141_911141_78	SARG|gi|696375142|ref|WP_032949690.1|	27.1	325	322	660	2.14e-30	120
k141_911141_78	SARG|gi|851981245|ref|WP_048240645.1|	27.1	325	322	660	2.14e-30	120
k141_911141_78	SARG|YP_002850217	27.4	325	322	660	2.90e-30	119
k141_911141_78	SARG|gi|851965596|ref|WP_048234849.1|	27.4	325	322	660	3.94e-30	119
k141_911141_78	SARG|gi|1002399350|ref|WP_061382108.1|	27.1	325	322	660	3.94e-30	119
k141_391688_2	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	59.7	243	241	252	1.30e-96	281
k141_391688_2	CARD|gb|AAG05188.1|ARO:3005068|ParR	38.5	226	241	235	8.38e-50	162
k141_391688_2	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	40.9	225	241	225	1.12e-47	156
k141_391688_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.2	224	241	228	2.18e-45	150
k141_391688_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	38.8	224	241	229	1.98e-43	145
k141_391688_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.8	226	241	229	1.74e-41	140
k141_391688_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.1	226	241	231	2.04e-40	137
k141_391688_2	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	34.1	232	241	239	3.94e-39	134
k141_391688_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.6	226	241	231	1.39e-37	130
k141_391688_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	33.9	227	241	230	1.90e-37	130
k141_709158_20	SARG|AAD51059	31.3	259	334	323	2.94e-31	119
k141_709158_20	SARG|AAD41881	30.9	259	334	323	7.89e-31	117
k141_709158_20	SARG|AAR37059	32.4	238	334	323	4.08e-30	115
k141_709158_20	SARG|gi|552942232|ref|WP_023043160.1|	32.2	236	334	323	1.09e-29	114
k141_709158_20	SARG|AAD42183	31.3	259	334	322	1.49e-29	114
k141_709158_20	SARG|AY082011.1.gene6.p01	31.8	236	334	323	7.77e-29	112
k141_709158_20	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	30.6	235	334	323	5.36e-27	107
k141_709158_23	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	44.4	117	376	235	2.70e-20	87.8
k141_709158_23	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.3	135	376	231	1.87e-17	79.7
k141_709158_23	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.0	117	376	232	2.59e-17	79.3
k141_709158_23	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	38.3	120	376	233	2.64e-17	79.3
k141_709158_23	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.9	117	376	232	3.54e-17	79.0
k141_709158_23	CARD|gb|ADM92605.1|ARO:3000553|adeR	36.8	133	376	247	4.55e-17	79.0
k141_709158_23	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.7	120	376	228	1.57e-16	77.0
k141_709158_23	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	41.3	121	376	239	2.57e-16	76.6
k141_709158_23	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.9	117	376	232	4.26e-16	75.9
k141_709158_23	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.0	117	376	232	4.26e-16	75.9
k141_709158_24	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.9	208	1428	361	1.26e-12	70.1
k141_709158_25	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.8	238	1337	361	8.76e-13	70.5
k141_709158_25	CARD|gb|ADM92605.1|ARO:3000553|adeR	30.3	122	1337	247	4.33e-09	57.8
k141_709158_25	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.4	135	1337	219	9.86e-09	56.2
k141_709158_33	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	25.3	364	659	579	1.12e-34	138
k141_709158_33	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	25.3	364	659	579	1.51e-34	137
k141_709158_33	SARG|gi|974588181|ref|WP_059178476.1|	33.9	186	659	646	1.46e-20	95.1
k141_709158_33	SARG|YP_001176128	33.9	186	659	646	1.46e-20	95.1
k141_572245_120	SARG|gb|AAG05915.1|ARO:3004074|MuxB	28.9	1043	1039	1043	1.51e-109	364
k141_572245_120	CARD|gb|AAC75137.1|ARO:3000794|mdtC	28.4	1048	1039	1025	1.05e-108	361
k141_572245_120	SARG|gb|BAE06006.1|ARO:3003705|mexN	28.3	1047	1039	1036	3.71e-102	343
k141_572245_120	SARG|YP_002800512	28.1	1086	1039	1057	3.28e-91	313
k141_572245_120	SARG|gi|940417834|ref|WP_055007142.1|	26.4	1067	1039	1063	1.73e-90	311
k141_572245_120	SARG|gi|950551359|ref|WP_057425316.1|	26.4	1066	1039	1063	1.73e-90	311
k141_572245_120	SARG|gi|950546578|ref|WP_057422848.1|	26.3	1066	1039	1063	2.36e-90	311
k141_572245_120	SARG|gi|514421161|ref|WP_016568324.1|	26.4	1067	1039	1063	3.24e-90	311
k141_572245_120	SARG|gi|489512421|ref|WP_003417270.1|	26.4	1067	1039	1063	3.24e-90	311
k141_572245_120	SARG|gi|671631846|ref|WP_031594729.1|	26.3	1066	1039	1063	4.44e-90	310
k141_572245_121	CARD|gb|AAG03546.1|ARO:3003679|TriA	28.2	326	405	383	2.43e-22	96.7
k141_572245_121	SARG|gi|763064330|ref|WP_043946082.1|	25.7	346	405	385	6.05e-16	77.8
k141_572245_121	SARG|gi|755835325|ref|WP_042591034.1|	25.7	346	405	385	8.12e-16	77.4
k141_572245_121	SARG|YP_002256705	25.4	346	405	385	1.09e-15	77.0
k141_572245_121	SARG|gi|746541139|ref|WP_039573465.1|	25.4	346	405	385	1.09e-15	77.0
k141_572245_121	SARG|gi|942503284|ref|WP_055335444.1|	25.4	346	405	385	1.46e-15	76.6
k141_572245_121	SARG|NP_521874	25.1	346	405	385	1.46e-15	76.6
k141_572245_121	SARG|gi|502972697|ref|WP_013207673.1|	25.4	346	405	385	1.96e-15	76.3
k141_572245_121	SARG|gi|746517374|ref|WP_039553500.1|	25.7	346	405	385	2.63e-15	75.9
k141_572245_121	SARG|gi|942479276|ref|WP_055325699.1|	25.4	346	405	385	2.63e-15	75.9
k141_595187_15	NCBI|WP_446913750.1|1|1|blaPFM-5|blaPFM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B2_metallo-beta-lactamase_PFM-5|AMR|beta-lactam	25.6	211	347	253	2.96e-13	67.8
k141_595187_15	SARG|gb|WP_156404660.1|ARO:3006967|PFM-3	24.6	211	347	253	4.01e-13	67.4
k141_595187_15	SARG|gb|MBU4627809.1|ARO:3007021|BioF	24.6	211	347	253	5.43e-13	67.0
k141_595187_15	SARG|gb|WP_057012521.1|ARO:3006966|PFM-2	24.2	211	347	253	9.97e-13	66.2
k141_595187_47	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	42.7	225	230	225	5.30e-54	172
k141_595187_47	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.4	230	230	230	4.56e-45	149
k141_595187_47	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	37.1	229	230	231	1.17e-42	143
k141_595187_47	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	37.5	232	230	252	2.90e-42	142
k141_595187_47	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	230	231	3.29e-42	142
k141_595187_47	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	230	231	9.25e-42	140
k141_595187_47	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.3	229	230	229	1.75e-41	140
k141_595187_47	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.5	228	230	231	2.60e-41	139
k141_595187_47	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.4	223	230	232	2.67e-41	139
k141_595187_47	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.5	228	230	231	3.67e-41	139
k141_595187_48	CARD|gb|BAB38260.1|ARO:3000830|cpxA	33.7	303	579	457	4.92e-38	145
k141_595187_48	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.5	249	579	354	3.55e-12	67.0
k141_595187_60	SARG|gb|AAV85982.1|ARO:3000535|macB	33.7	403	408	644	3.70e-62	210
k141_595187_60	SARG|gi|736472622|ref|WP_034494292.1|	31.3	403	408	648	1.16e-47	171
k141_595187_60	SARG|gi|1035706844|ref|WP_064548272.1|	30.8	409	408	648	3.93e-46	167
k141_595187_60	SARG|gi|1035670474|ref|WP_064517458.1|	30.4	404	408	648	5.41e-46	166
k141_595187_60	SARG|gi|1035717981|ref|WP_064557480.1|	30.4	404	408	648	5.41e-46	166
k141_595187_60	SARG|gi|766961649|ref|WP_044860626.1|	29.7	404	408	648	1.03e-45	166
k141_595187_60	SARG|gi|921980855|ref|WP_053272142.1|	29.7	404	408	648	1.03e-45	166
k141_595187_60	SARG|gi|487369254|ref|WP_001643240.1|	29.7	404	408	648	1.41e-45	165
k141_595187_60	SARG|gi|974633183|ref|WP_059219858.1|	29.7	404	408	648	1.41e-45	165
k141_595187_60	SARG|gi|895964662|ref|WP_049044610.1|	30.0	404	408	648	1.94e-45	165
k141_595187_61	SARG|gi|754927849|ref|WP_042284850.1|	48.9	219	229	648	2.12e-73	233
k141_595187_61	SARG|gi|835330218|ref|WP_047457825.1|	48.9	219	229	648	2.97e-73	233
k141_595187_61	SARG|YP_001453760	48.9	219	229	648	2.97e-73	233
k141_595187_61	SARG|gi|976150171|ref|WP_059308384.1|	48.2	228	229	646	7.88e-73	232
k141_595187_61	SARG|gi|757782629|ref|WP_043001213.1|	48.4	219	229	648	1.61e-72	231
k141_595187_61	SARG|gi|502669352|ref|WP_012905216.1|	46.5	226	229	648	1.61e-72	231
k141_595187_61	SARG|gi|992390012|ref|WP_061077002.1|	48.4	219	229	648	1.61e-72	231
k141_595187_61	SARG|gi|763407609|ref|WP_044264203.1|	48.4	219	229	648	1.61e-72	231
k141_595187_61	SARG|gi|968563772|ref|WP_058587854.1|	48.4	219	229	648	2.25e-72	231
k141_595187_61	SARG|YP_001176128	47.5	221	229	646	4.27e-72	230
k141_595187_62	SARG|gi|1011931657|ref|WP_062740776.1|	23.0	361	423	371	2.59e-22	96.7
k141_595187_62	SARG|gi|503132228|ref|WP_013366889.1|	23.0	361	423	371	3.52e-22	96.3
k141_595187_62	SARG|gi|485863445|ref|WP_001462366.1|	23.3	390	423	371	3.52e-22	96.3
k141_595187_62	SARG|gi|545249103|ref|WP_021547424.1|	23.3	390	423	371	3.52e-22	96.3
k141_595187_62	SARG|gi|486191968|ref|WP_001544419.1|	23.3	390	423	371	6.48e-22	95.5
k141_595187_62	SARG|gi|693089169|ref|WP_032248590.1|	23.3	390	423	371	6.48e-22	95.5
k141_595187_62	SARG|gi|446669097|ref|WP_000746443.1|	23.3	390	423	371	6.48e-22	95.5
k141_595187_62	SARG|gi|446669112|ref|WP_000746458.1|	23.8	391	423	371	8.79e-22	95.1
k141_595187_62	SARG|gi|983456720|ref|WP_060617235.1|	23.1	390	423	371	8.79e-22	95.1
k141_595187_62	SARG|gi|446669108|ref|WP_000746454.1|	23.3	390	423	371	8.79e-22	95.1
k141_324132_18	CARD|gb|AAC75429.1|ARO:3000833|evgS	39.4	104	122	1197	5.90e-14	65.9
k141_324132_18	CARD|gb|AAG06465.1|ARO:3005063|cprR	38.0	108	122	223	1.82e-12	60.5
k141_324132_24	CARD|gb|AAC75429.1|ARO:3000833|evgS	33.6	122	132	1197	1.13e-13	65.5
k141_324132_91	SARG|YP_001373621	35.2	293	309	318	2.91e-53	176
k141_324132_91	SARG|P42332	36.0	297	309	306	5.90e-53	174
k141_324132_91	SARG|ABB80128	36.0	297	309	306	8.31e-53	174
k141_324132_91	SARG|gi|500448961|gb|EOP61695.1|	35.0	297	309	306	1.17e-52	174
k141_324132_91	SARG|AAD21213	35.7	297	309	306	1.17e-52	174
k141_324132_91	SARG|gi|500194536|ref|WP_011867743.1|	35.1	299	309	306	1.65e-52	173
k141_324132_91	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	36.2	293	309	306	1.65e-52	173
k141_324132_91	SARG|gi|510143239|gb|AGN36970.1|	36.2	293	309	313	1.99e-52	173
k141_324132_91	SARG|gi|500465078|gb|EOP76697.1|	35.0	297	309	306	2.32e-52	173
k141_324132_91	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	35.1	305	309	307	1.86e-51	171
k141_324132_113	SARG|gb|APB03222.1|ARO:3003992|rphB	35.0	337	803	884	4.20e-46	176
k141_324132_113	NCBI|WP_087348261.1|1|1|rphD|rphD||2|rifamycin|rifamycin|rifamycin-inactivating_phosphotransferase_RphD|AMR|rifamycin	34.0	338	803	872	1.27e-45	175
k141_324132_113	SARG|gb|AIA08936.1|ARO:3000444|rphA	36.3	339	803	865	1.26e-44	172
k141_324132_113	NCBI|WP_087347987.1|1|1|rphC|rphC||2|rifamycin|rifamycin|rifamycin-inactivating_phosphotransferase_RphC|AMR|rifamycin	33.2	337	803	868	9.63e-43	166
k141_324132_118	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.5	513	663	655	1.49e-88	288
k141_324132_118	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.5	513	663	655	2.91e-88	288
k141_324132_118	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.1	513	663	655	2.91e-88	288
k141_324132_118	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.5	513	663	655	4.07e-88	287
k141_324132_118	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.5	513	663	655	1.11e-87	286
k141_324132_118	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.3	513	663	655	2.17e-87	285
k141_324132_118	SARG|gb|AKA86814|ARO:3003746|optrA	34.3	513	663	655	2.17e-87	285
k141_324132_118	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.3	513	663	655	4.24e-87	285
k141_324132_118	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.3	513	663	655	4.24e-87	285
k141_324132_118	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.3	513	663	655	4.24e-87	285
k141_324132_170	SARG|gb|NP_388442.1|ARO:3004476|vmlR	26.3	224	242	547	6.04e-10	57.8
k141_324132_170	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	25.5	204	242	494	2.55e-09	55.8
k141_324132_170	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	205	242	655	3.78e-09	55.5
k141_324132_170	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	205	242	655	3.78e-09	55.5
k141_324132_170	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.3	205	242	655	9.18e-09	54.3
k141_324132_170	SARG|gb|CDO61516.1|ARO:3003949|efrB	24.8	157	242	362	1.28e-08	53.5
k141_324132_170	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	205	242	655	4.00e-08	52.4
k141_324132_170	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	205	242	655	4.00e-08	52.4
k141_324132_170	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	205	242	655	4.00e-08	52.4
k141_324132_170	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	205	242	655	4.00e-08	52.4
k141_324132_171	SARG|AAM11668	22.7	375	559	381	3.74e-10	60.8
k141_324132_171	SARG|gb|AHM76768.1|ARO:3002106|CMY-93	22.9	376	559	381	1.16e-09	59.3
k141_324132_171	SARG|gb|AHL39324.1|ARO:3002095|CMY-82	22.9	376	559	381	2.05e-09	58.5
k141_324132_171	megares|MEG_1983|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	22.9	376	559	382	2.06e-09	58.5
k141_324132_171	NCBI|WP_420354075.1|1|1|blaCMY-211|blaCMY|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_CMY-211|AMR|beta-lactam	22.8	377	559	382	2.73e-09	58.2
k141_324132_171	SARG|gb|AFU25638.1|ARO:3002096|CMY-83	22.9	376	559	381	3.61e-09	57.8
k141_324132_196	SARG|gi|970301657|ref|WP_058672678.1|	24.5	323	522	371	1.71e-08	55.5
k141_324132_197	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	24.6	1057	1048	1074	9.90e-76	270
k141_324132_197	SARG|YP_350221	23.8	1043	1048	1009	2.30e-75	268
k141_324132_197	CARD|gb|AAL14440.1|ARO:3000775|adeB	24.9	1059	1048	1035	5.62e-75	267
k141_324132_197	SARG|gi|966514950|ref|WP_058531469.1|	24.0	1071	1048	1055	9.32e-75	266
k141_324132_197	SARG|CAY51926	23.3	1045	1048	1008	1.05e-74	266
k141_324132_197	SARG|gi|966510466|ref|WP_058527057.1|	24.2	1074	1048	1056	1.27e-74	266
k141_324132_197	SARG|gi|966396486|ref|WP_058441292.1|	24.3	1081	1048	1063	3.38e-74	265
k141_324132_197	SARG|YP_348488	24.5	1055	1048	1043	5.10e-74	264
k141_324132_197	SARG|gi|852273548|ref|WP_048328542.1|	25.0	1055	1048	1043	1.27e-73	263
k141_324132_197	SARG|YP_001350280	24.4	1039	1048	1018	3.31e-73	261
k141_324132_209	SARG|gi|851912779|ref|WP_048215868.1|	56.1	337	347	660	1.04e-134	397
k141_324132_209	SARG|gi|489931383|ref|WP_003834702.1|	55.5	337	347	660	4.67e-133	393
k141_324132_209	SARG|gi|851935911|ref|WP_048224705.1|	55.5	337	347	660	6.60e-133	392
k141_324132_209	SARG|gi|851965596|ref|WP_048234849.1|	55.5	337	347	660	6.60e-133	392
k141_324132_209	SARG|gi|696369048|ref|WP_032944060.1|	55.5	337	347	660	6.60e-133	392
k141_324132_209	SARG|YP_002850217	55.2	337	347	660	9.32e-133	392
k141_324132_209	SARG|gi|1002399350|ref|WP_061382108.1|	55.2	337	347	660	1.32e-132	392
k141_324132_209	SARG|gi|507083067|ref|WP_016153816.1|	55.2	337	347	660	2.63e-132	391
k141_324132_209	SARG|gi|507086291|ref|WP_016157032.1|	55.2	337	347	660	2.63e-132	391
k141_324132_209	SARG|gi|696375142|ref|WP_032949690.1|	55.2	337	347	660	2.63e-132	391
k141_324132_210	SARG|gb|AAG06942.1|ARO:3002985|arnA	49.6	246	306	662	2.94e-78	249
k141_324132_210	SARG|gi|486356316|ref|WP_001592400.1|	44.8	286	306	660	4.23e-77	246
k141_324132_210	SARG|gi|446783033|ref|WP_000860289.1|	43.2	294	306	660	5.93e-77	246
k141_324132_210	SARG|gi|545266912|ref|WP_021557970.1|	43.2	294	306	660	5.93e-77	246
k141_324132_210	SARG|B7LM76	46.5	286	306	660	5.93e-77	246
k141_324132_210	SARG|gi|553941003|ref|WP_023147955.1|	43.2	294	306	660	5.93e-77	246
k141_324132_210	SARG|YP_002329903	43.2	294	306	660	5.93e-77	246
k141_324132_210	SARG|gi|446783037|ref|WP_000860293.1|	43.2	294	306	660	5.93e-77	246
k141_324132_210	SARG|gi|446783059|ref|WP_000860315.1|	42.9	294	306	660	8.32e-77	246
k141_324132_210	SARG|gi|486404556|ref|WP_001607766.1|	43.2	294	306	660	1.17e-76	245
k141_324132_211	SARG|gb|AAC75314.1|ARO:3003578|pmrF	47.6	317	324	322	4.74e-87	263
k141_324132_213	SARG|gb|CDO12042.1|ARO:3005053|ArnT	29.4	523	565	551	1.70e-34	136
k141_324132_227	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	520	534	655	3.39e-77	254
k141_324132_227	SARG|gb|AKA86814|ARO:3003746|optrA	31.3	520	534	655	3.39e-77	254
k141_324132_227	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	520	534	655	9.25e-77	253
k141_324132_227	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	520	534	655	9.25e-77	253
k141_324132_227	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	520	534	655	9.25e-77	253
k141_324132_227	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	520	534	655	9.25e-77	253
k141_324132_227	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	520	534	655	9.25e-77	253
k141_324132_227	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	520	534	655	9.25e-77	253
k141_324132_227	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.2	520	534	655	9.25e-77	253
k141_324132_227	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	520	534	655	9.25e-77	253
k141_324132_259	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	47.1	242	242	252	3.37e-67	207
k141_324132_259	CARD|gb|AAG05188.1|ARO:3005068|ParR	40.8	233	242	235	4.27e-53	170
k141_324132_259	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	41.2	238	242	228	2.22e-51	166
k141_324132_259	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	37.1	229	242	225	1.62e-50	163
k141_324132_259	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.4	229	242	231	9.76e-48	156
k141_324132_259	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.4	229	242	231	9.76e-48	156
k141_324132_259	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.7	228	242	232	4.48e-46	152
k141_324132_259	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.7	228	242	232	4.48e-46	152
k141_324132_259	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.1	235	242	231	1.23e-45	151
k141_324132_259	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.3	235	242	231	1.73e-45	150
k141_324132_260	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	23.0	256	452	364	3.24e-11	63.5
k141_324132_260	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	23.0	256	452	364	3.24e-11	63.5
k141_868821_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.0	124	243	219	1.39e-07	49.7
k141_868821_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.0	124	243	219	1.39e-07	49.7
k141_868821_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.0	124	243	220	1.40e-07	49.7
k141_868821_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.0	124	243	220	1.90e-07	49.3
k141_868821_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.8	124	243	220	3.48e-07	48.5
k141_868821_22	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.8	229	722	1197	1.74e-26	115
k141_868821_32	SARG|gi|559226183|ref|WP_023581296.1|	21.1	399	430	369	1.26e-12	67.8
k141_868821_32	SARG|gi|739066754|ref|WP_036938162.1|	21.2	397	430	369	5.35e-11	62.8
k141_868821_32	SARG|gi|739100685|ref|WP_036971354.1|	19.5	364	430	369	5.30e-10	59.7
k141_868821_32	SARG|gi|896239619|ref|WP_049236948.1|	19.5	364	430	369	7.06e-10	59.3
k141_868821_32	SARG|gi|490367950|ref|WP_004247613.1|	19.5	364	430	369	7.06e-10	59.3
k141_868821_32	SARG|gi|516438819|ref|WP_017827731.1|	19.5	364	430	369	7.06e-10	59.3
k141_868821_32	SARG|gi|810389049|ref|WP_046335163.1|	19.5	364	430	369	1.25e-09	58.5
k141_868821_32	SARG|gi|983379772|ref|WP_060557066.1|	22.0	364	430	369	1.25e-09	58.5
k141_868821_32	SARG|CP004022.1.gene757.p01	19.5	364	430	369	1.25e-09	58.5
k141_868821_32	SARG|gi|857587769|emb|CRL59467.1|	19.2	360	430	369	1.67e-09	58.2
k141_868821_33	SARG|gi|835330218|ref|WP_047457825.1|	47.5	219	227	648	2.56e-61	201
k141_868821_33	SARG|YP_001453760	47.5	219	227	648	2.56e-61	201
k141_868821_33	SARG|gi|555268037|ref|WP_023249477.1|	47.5	219	227	648	3.58e-61	201
k141_868821_33	SARG|gi|810369244|ref|WP_046334012.1|	47.9	219	227	647	4.92e-61	201
k141_868821_33	SARG|gi|950834222|ref|WP_057524365.1|	47.9	219	227	648	5.00e-61	201
k141_868821_33	SARG|gi|922019548|ref|WP_053299973.1|	47.9	219	227	648	5.00e-61	201
k141_868821_33	SARG|gi|446048017|ref|WP_000125872.1|	47.9	219	227	648	5.00e-61	201
k141_868821_33	SARG|gi|959108022|ref|WP_058113001.1|	47.9	219	227	648	5.00e-61	201
k141_868821_33	SARG|Q5PGK9	47.9	219	227	648	5.00e-61	201
k141_868821_33	SARG|gi|1004393797|ref|WP_061537938.1|	47.9	219	227	648	5.00e-61	201
k141_868821_36	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.8	221	422	364	3.65e-08	53.9
k141_868821_36	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.8	221	422	364	3.65e-08	53.9
k141_868821_37	CARD|gb|AAK37618.1|ARO:3005008|TxR	35.0	351	483	318	3.48e-51	175
k141_868821_42	CARD|gb|VWQ00850.1|ARO:3003843|leuO	29.4	306	304	314	9.24e-31	116
k141_868821_54	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.0	222	229	228	7.00e-37	128
k141_868821_54	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.3	231	229	232	4.74e-35	123
k141_868821_54	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.3	231	229	232	4.74e-35	123
k141_868821_54	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.9	225	229	231	7.12e-34	120
k141_868821_54	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	28.7	230	229	231	2.35e-31	114
k141_868821_54	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	28.7	230	229	231	2.35e-31	114
k141_868821_54	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	31.6	225	229	232	1.86e-30	111
k141_868821_54	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	29.0	231	229	231	2.55e-30	111
k141_868821_54	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	27.8	230	229	231	9.91e-30	109
k141_868821_54	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	29.0	221	229	225	1.58e-25	98.6
k141_868821_75	SARG|gi|445996695|ref|WP_000074550.1|	31.5	254	274	309	2.91e-31	117
k141_868821_75	SARG|gb|ADZ12699.1|ARO:3005091|RanA	32.9	210	274	258	1.46e-30	114
k141_868821_75	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.5	216	274	343	1.11e-20	89.0
k141_868821_75	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	29.7	219	274	325	4.65e-17	78.6
k141_868821_75	SARG|gb|AAA26793|ARO:3003748|oleC	29.7	219	274	325	8.69e-17	77.8
k141_868821_75	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	28.0	211	274	293	2.85e-13	67.4
k141_868821_75	SARG|gb|AAR96051.1|ARO:3002894|otrC	33.3	90	274	351	2.57e-06	47.0
k141_868821_75	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	33.3	90	274	351	2.57e-06	47.0
k141_868821_76	SARG|gb|ADZ12700.1|ARO:3005090|RanB	26.1	238	375	253	6.42e-23	95.5
k141_868821_77	NCBI|WP_042649073.1|1|1|mcr-3_set|mcr-3_set||2|COLISTIN|COLISTIN|MCR-3-related_phosphoethanolamine--lipid_A_transferase|AMR|peptide	28.4	370	616	541	7.93e-31	125
k141_868821_77	NCBI|WP_039039919.1|1|1|mcr-3.38|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.38|AMR|peptide	29.8	315	616	540	1.91e-30	124
k141_868821_77	SARG|WP_065804663.1	28.9	315	616	541	2.59e-30	124
k141_868821_77	NCBI|WP_136512112.1|1|1|mcr-3.29|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.29|AMR|peptide	28.9	315	616	541	2.59e-30	124
k141_868821_77	NCBI|WP_094308975.1|1|1|mcr-3.22|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.22|AMR|peptide	28.9	315	616	541	3.47e-30	124
k141_868821_77	NCBI|WP_188331896.1|1|1|mcr-3.37|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.37|AMR|peptide	29.7	317	616	540	4.63e-30	123
k141_868821_77	CARD|gb|BCG06510.1|ARO:3007266|MCR-3.20	28.6	315	616	447	5.85e-30	122
k141_868821_77	SARG|gb|AUN87920.1|ARO:3004500|MCR-3.11	28.9	315	616	541	6.27e-30	123
k141_868821_77	NCBI|WP_111273844.1|1|1|mcr-3.15|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.15|AMR|peptide	29.5	315	616	540	1.12e-29	122
k141_868821_77	NCBI|WP_188331890.1|1|1|mcr-3.31|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.31|AMR|peptide	29.3	317	616	540	1.12e-29	122
k141_868821_80	SARG|NP_348076	27.3	678	702	652	8.17e-82	271
k141_868821_80	SARG|YP_002850805	27.9	677	702	652	1.16e-80	268
k141_868821_80	SARG|ZP_02952732	27.8	677	702	652	3.18e-79	265
k141_868821_80	SARG|ZP_02632674	27.8	677	702	660	3.78e-79	265
k141_868821_80	SARG|L20800.gene.p01	27.8	677	702	652	1.66e-78	263
k141_868821_80	SARG|L42544.gene.p01	27.6	682	702	651	2.26e-78	262
k141_868821_80	SARG|AAV80410	27.4	682	702	651	3.17e-77	259
k141_868821_80	SARG|AJ295238.gene.p01	26.4	683	702	639	4.35e-67	231
k141_868821_80	SARG|ABN80187	27.6	682	702	640	4.43e-67	231
k141_868821_80	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.1	682	702	639	6.02e-67	231
k141_438224_9	CARD|gb|AAD51348.1|ARO:3003066|smeR	42.6	230	234	229	3.96e-50	162
k141_438224_9	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.7	232	234	228	3.10e-46	152
k141_438224_9	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.4	227	234	231	3.78e-45	149
k141_438224_9	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.1	226	234	219	1.51e-44	147
k141_438224_9	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	35.0	234	234	233	3.94e-42	142
k141_438224_9	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.7	229	234	232	3.36e-40	137
k141_438224_9	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.4	231	234	231	4.62e-40	136
k141_438224_9	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.6	235	234	235	5.14e-40	136
k141_438224_9	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.9	231	234	231	1.30e-39	135
k141_438224_9	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	35.4	237	234	232	1.88e-39	135
k141_438224_25	SARG|gi|665898917|ref|WP_031266123.1|	29.9	154	180	139	5.98e-08	48.5
k141_438224_25	SARG|gi|657290186|ref|WP_029377637.1|	27.9	154	180	139	1.58e-07	47.4
k141_438224_25	SARG|gi|835427938|ref|WP_047502624.1|	27.0	152	180	139	1.10e-06	45.1
k141_438224_25	SARG|gi|948792952|ref|WP_056935383.1|	29.2	154	180	139	1.51e-06	44.7
k141_438224_25	SARG|gi|518299227|ref|WP_019469435.1|	26.6	154	180	139	1.51e-06	44.7
k141_438224_25	SARG|gi|872022881|emb|CRV27548.1|	27.3	154	180	139	7.50e-06	42.7
k141_438224_44	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	33.8	847	840	703	8.09e-132	409
k141_438224_52	NCBI|WP_167809787.1|1|1|blaYOC-1|blaYOC|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_YOC-1|AMR|beta-lactam	25.0	344	402	385	5.92e-16	77.8
k141_438224_52	NCBI|WP_290468365.1|1|1|blaPSZ-1|blaPSZ|hydrolase|2|beta-lactam|beta-lactam|class_C_beta-lactamase_PSZ-1|AMR|beta-lactam	27.7	249	402	379	1.08e-14	73.9
k141_438224_52	NCBI|WP_280147732.1|1|1|blaAMZ-1|blaAMZ|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_AMZ-1|AMR|beta-lactam	28.7	254	402	396	5.03e-14	72.0
k141_438224_52	NCBI|WP_420354056.1|1|1|blaADC-385|blaADC|hydrolase|2|CEPHALOSPORIN|beta-lactam|extended-spectrum_class_C_beta-lactamase_ADC-385|AMR|beta-lactam	25.6	234	402	383	6.38e-09	56.2
k141_438224_52	SARG|gb|WP_150823460.1|ARO:3006377|ADC-208	26.6	233	402	383	6.38e-09	56.2
k141_438224_52	SARG|gb|WP_150823455.1|ARO:3006370|ADC-201	26.4	227	402	383	1.13e-08	55.5
k141_438224_52	SARG|gb|WP_150823462.1|ARO:3006379|ADC-210	26.4	227	402	383	1.13e-08	55.5
k141_438224_52	SARG|gb|CAK95245.1|ARO:3003860|ADC-16	26.4	227	402	383	1.13e-08	55.5
k141_438224_52	NCBI|WP_009389984.1|1|1|blaADC-295|blaADC|hydrolase|2|CEPHALOSPORIN|beta-lactam|extended-spectrum_class_C_beta-lactamase_ADC-295|AMR|beta-lactam	26.1	234	402	383	4.69e-08	53.5
k141_438224_52	SARG|gb|AAT70411.1|ARO:3003853|ADC-7	26.1	234	402	383	6.23e-08	53.1
k141_438224_91	SARG|gi|486458841|gb|EOE03251.1|	36.0	75	231	237	2.24e-08	52.0
k141_438224_93	CARD|gb|WKR28567.1|ARO:3007678|IreK	33.2	238	455	718	3.48e-24	104
k141_438224_102	CARD|gb|ALH22601.1|ARO:3000620|adeL	39.2	291	315	337	3.57e-58	189
k141_438224_127	SARG|gi|486458841|gb|EOE03251.1|	40.0	70	231	237	2.62e-09	54.7
k141_438224_136	SARG|gi|647122398|ref|WP_025641541.1|	34.9	195	232	202	8.14e-29	106
k141_438224_136	SARG|gi|552937074|ref|WP_023042301.1|	36.5	192	232	202	2.26e-28	105
k141_438224_136	SARG|AAR37061	36.5	192	232	202	2.26e-28	105
k141_438224_136	megares|MEG_7431|Drugs|Glycopeptide|VanD-type_resistance_protein|VANHD_3	37.6	181	232	192	3.48e-28	104
k141_438224_136	SARG|AAD51061	34.9	192	232	202	4.46e-28	104
k141_438224_136	megares|MEG_7436|Drugs|Glycopeptide|VanD-type_resistance_protein|VANHD_3	35.9	181	232	192	6.88e-28	103
k141_438224_136	SARG|ACM47288	34.9	192	232	202	3.42e-27	102
k141_438224_136	SARG|AAZ98840	34.9	195	232	203	3.51e-27	102
k141_438224_136	SARG|AAD42185	35.4	192	232	202	4.81e-27	102
k141_438224_136	megares|MEG_7435|Drugs|Glycopeptide|VanD-type_resistance_protein|VANHD_3	35.9	181	232	192	5.29e-27	101
k141_662241_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	29.8	121	394	229	3.56e-19	84.7
k141_662241_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	32.5	120	394	225	1.23e-12	65.9
k141_662241_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	32.5	120	394	225	1.23e-12	65.9
k141_120938_15	SARG|YP_001401994	31.0	539	661	563	9.67e-59	206
k141_120938_15	SARG|AAS61092	31.0	539	661	563	1.34e-58	206
k141_120938_15	SARG|gi|740410309|ref|WP_038243756.1|	30.7	541	661	563	9.31e-58	203
k141_120938_15	SARG|ZP_04615639	30.3	525	661	543	6.08e-57	201
k141_120938_15	SARG|YP_001605795	30.9	540	661	562	1.21e-56	200
k141_120938_15	SARG|ZP_04638974	31.4	541	661	563	1.23e-56	200
k141_120938_15	SARG|ZP_04631861	31.0	525	661	543	3.06e-56	199
k141_120938_15	SARG|ZP_04630103	30.7	525	661	543	2.12e-55	196
k141_120938_15	SARG|YP_001007250	31.1	541	661	563	2.23e-55	197
k141_120938_15	SARG|ZP_04623897	30.9	525	661	543	4.03e-55	196
k141_120938_21	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	31.6	247	248	293	3.65e-33	120
k141_120938_21	SARG|gi|446048013|ref|WP_000125868.1|	28.6	210	248	648	9.19e-17	78.2
k141_120938_21	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	26.3	186	248	505	7.44e-07	48.5
k141_120938_21	SARG|gi|738121094|ref|WP_036079133.1|	22.0	200	248	493	3.17e-06	46.6
k141_120938_21	SARG|gi|495453058|ref|WP_008177752.1|	23.2	185	248	492	7.58e-06	45.4
k141_393490_9	SARG|gb|AAV85982.1|ARO:3000535|macB	36.6	243	270	644	1.26e-34	130
k141_393490_9	SARG|gi|895865878|ref|WP_048974758.1|	37.2	223	270	646	2.67e-30	118
k141_393490_9	SARG|gi|445996714|ref|WP_000074569.1|	28.4	215	270	309	4.41e-19	84.0
k141_393490_9	SARG|gi|445996719|ref|WP_000074574.1|	28.3	198	270	309	6.07e-19	83.6
k141_393490_9	SARG|gi|500465078|gb|EOP76697.1|	26.7	217	270	306	1.11e-18	82.8
k141_393490_9	SARG|gi|895736250|emb|COF64653.1|	27.8	198	270	309	1.15e-18	82.8
k141_393490_9	SARG|gi|446110087|ref|WP_000187942.1|	27.8	198	270	309	1.15e-18	82.8
k141_393490_9	SARG|gi|445996710|ref|WP_000074565.1|	27.8	198	270	309	1.15e-18	82.8
k141_393490_9	SARG|gi|542061059|gb|ERI11611.1|	27.9	201	270	316	1.70e-18	82.4
k141_393490_9	SARG|gi|895808656|emb|COR83787.1|	28.9	201	270	309	2.16e-18	82.0
k141_393490_23	SARG|gb|AAD08227.1|ARO:3003964|hp1181	33.0	370	424	443	3.59e-40	147
k141_393490_23	SARG|AAR14158	30.9	136	424	392	5.73e-12	65.9
k141_393490_23	SARG|CAQ51492	30.9	136	424	393	5.75e-12	65.9
k141_393490_23	SARG|gi|505141122|ref|WP_015328224.1|	30.9	136	424	393	5.75e-12	65.9
k141_393490_23	SARG|CAA76069	30.9	136	424	400	5.90e-12	65.9
k141_393490_23	SARG|Y15510.gene.p01	30.9	136	424	400	5.90e-12	65.9
k141_393490_23	SARG|P51564	30.9	136	424	400	1.39e-11	64.7
k141_393490_23	SARG|YP_002152117	34.7	118	424	398	7.71e-11	62.4
k141_393490_23	SARG|ZP_03841721	34.7	118	424	398	1.03e-10	62.0
k141_393490_23	SARG|CP004022.1.gene2534.p01	34.7	118	424	398	1.03e-10	62.0
k141_393490_24	SARG|gi|695840638|ref|WP_032753940.1|	32.3	127	988	646	2.48e-09	60.1
k141_393490_24	SARG|gi|852138723|ref|WP_048293411.1|	32.3	127	988	646	4.28e-09	59.3
k141_393490_24	SARG|gi|829908959|ref|WP_047362283.1|	31.4	121	988	646	4.28e-09	59.3
k141_393490_24	SARG|gi|496081332|ref|WP_008805839.1|	32.3	127	988	646	4.28e-09	59.3
k141_393490_24	SARG|gi|751264306|ref|WP_040974017.1|	32.3	127	988	646	4.28e-09	59.3
k141_393490_24	SARG|gi|1031862522|ref|WP_064180366.1|	32.3	127	988	646	4.28e-09	59.3
k141_393490_24	SARG|gi|1006477526|ref|WP_061771940.1|	31.4	121	988	646	4.28e-09	59.3
k141_393490_24	SARG|gi|556492128|ref|WP_023339842.1|	32.3	127	988	646	4.28e-09	59.3
k141_393490_24	SARG|gi|742128296|gb|AJA96431.1|	32.3	127	988	646	4.28e-09	59.3
k141_393490_24	SARG|gi|822022298|ref|WP_046882271.1|	32.3	127	988	646	5.63e-09	58.9
k141_393490_28	SARG|gb|AAG04750.1|ARO:3004077|PmpM	41.9	458	463	477	9.87e-107	324
k141_393490_28	SARG|NP_934523	38.8	441	463	456	3.57e-95	293
k141_393490_28	SARG|Q8D9N8	38.5	441	463	456	7.10e-95	293
k141_393490_28	SARG|YP_001445425	38.4	443	463	456	7.10e-95	293
k141_393490_28	SARG|gb|BAD89844.2|ARO:3000753|abeM	38.2	435	463	448	1.09e-91	284
k141_393490_28	SARG|gi|490204266|ref|WP_004102709.1|	37.4	454	463	457	5.58e-91	283
k141_393490_28	SARG|gi|556469366|ref|WP_023321121.1|	37.9	454	463	457	1.56e-90	281
k141_393490_28	SARG|gi|515713142|ref|WP_017145742.1|	37.4	454	463	457	4.38e-90	280
k141_393490_28	SARG|gi|486126563|ref|WP_001512792.1|	37.5	451	463	457	4.85e-89	278
k141_393490_28	SARG|gi|754964131|ref|WP_042320052.1|	36.6	454	463	457	6.83e-89	277
k141_393490_36	SARG|gi|1035706844|ref|WP_064548272.1|	39.9	218	225	648	1.42e-40	145
k141_393490_36	SARG|gi|1035670474|ref|WP_064517458.1|	39.0	218	225	648	2.69e-40	144
k141_393490_36	SARG|gi|1035717981|ref|WP_064557480.1|	39.0	218	225	648	2.69e-40	144
k141_393490_36	SARG|Q83LR7	40.4	218	225	648	3.70e-40	144
k141_393490_36	SARG|gi|647325472|ref|WP_025760953.1|	40.4	218	225	648	3.70e-40	144
k141_393490_36	SARG|gi|647323678|ref|WP_025760497.1|	40.4	218	225	648	3.70e-40	144
k141_393490_36	SARG|gi|555268037|ref|WP_023249477.1|	39.0	218	225	648	7.01e-40	143
k141_393490_36	SARG|gi|736472622|ref|WP_034494292.1|	38.5	218	225	648	7.01e-40	143
k141_393490_36	SARG|gi|924626178|ref|WP_053530123.1|	39.0	218	225	648	9.65e-40	143
k141_393490_36	SARG|gi|446110307|ref|WP_000188162.1|	39.9	218	225	648	9.65e-40	143
k141_393490_54	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.1	111	143	228	3.43e-16	71.2
k141_393490_54	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.0	120	143	204	5.06e-13	62.4
k141_393490_54	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.3	120	143	231	2.55e-11	58.2
k141_393490_54	CARD|gb|AAD51348.1|ARO:3003066|smeR	30.6	121	143	229	1.75e-10	55.8
k141_393490_54	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.0	118	143	232	1.70e-09	53.1
k141_393490_54	CARD|gb|ATC67679.1|ARO:3000838|arlR	27.9	122	143	219	5.53e-09	51.6
k141_393490_54	CARD|gb|AAG06465.1|ARO:3005063|cprR	28.1	121	143	223	2.05e-08	50.1
k141_393490_54	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.3	127	143	219	9.76e-08	48.1
k141_393490_54	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.3	127	143	219	9.76e-08	48.1
k141_393490_54	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.3	127	143	220	9.83e-08	48.1
k141_393490_56	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.3	112	123	229	1.33e-16	71.6
k141_393490_56	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.2	116	123	228	1.02e-13	63.9
k141_393490_56	CARD|gb|ADM92605.1|ARO:3000553|adeR	28.8	118	123	247	1.25e-13	63.9
k141_393490_56	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.7	104	123	1197	1.94e-10	55.8
k141_121365_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.0	228	739	664	5.39e-28	119
k141_121365_4	SARG|gi|917203192|ref|WP_051809904.1|	23.4	569	739	620	5.55e-26	112
k141_121365_4	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.9	495	739	579	6.05e-26	112
k141_121365_4	SARG|gi|501350226|ref|WP_012381861.1|	28.4	236	739	603	9.07e-26	111
k141_121365_4	SARG|gi|917127754|ref|WP_051734466.1|	22.6	566	739	620	9.78e-26	111
k141_121365_4	SARG|gi|764446018|ref|WP_044369325.1|	22.2	558	739	605	1.22e-25	111
k141_121365_4	SARG|gi|799286378|ref|WP_045936958.1|	22.6	566	739	620	1.30e-25	111
k141_121365_4	SARG|gi|926376632|ref|WP_053705806.1|	22.6	566	739	620	1.30e-25	111
k141_121365_4	SARG|gi|926294973|ref|WP_053631154.1|	22.6	566	739	620	1.30e-25	111
k141_121365_4	SARG|gi|930482089|ref|WP_054228897.1|	27.9	283	739	599	1.57e-25	110
k141_121365_32	CARD|gb|ADM92605.1|ARO:3000553|adeR	33.8	77	125	247	4.75e-07	45.8
k141_121365_33	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.5	204	211	204	5.00e-24	93.6
k141_121365_33	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	23.5	213	211	219	1.49e-08	52.0
k141_121365_33	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	23.5	213	211	219	1.49e-08	52.0
k141_121365_33	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	23.5	213	211	220	1.50e-08	52.0
k141_121365_33	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	23.5	213	211	220	2.05e-08	51.6
k141_121365_33	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.1	103	211	220	2.05e-08	51.6
k141_121365_33	SARG|ZP_02848503	29.1	103	211	221	1.79e-07	48.9
k141_121365_33	CARD|gb|AAD51348.1|ARO:3003066|smeR	29.8	84	211	229	7.30e-06	44.3
k141_121365_35	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	37.9	346	386	379	3.66e-59	195
k141_121365_35	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	37.9	346	386	416	9.19e-59	195
k141_121365_35	SARG|CP001581.1.gene3143.p01	34.0	335	386	344	3.98e-55	184
k141_121365_35	SARG|gb|CAL84423.1|ARO:3004146|cfrC	33.7	335	386	344	3.98e-55	184
k141_121365_35	SARG|gb|BAD63613.1|ARO:3002816|clbC	35.5	358	386	350	2.38e-50	171
k141_121365_35	SARG|VXQ21601.1	34.4	340	386	344	5.65e-50	170
k141_121365_35	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	34.4	343	386	349	1.26e-49	169
k141_121365_35	SARG|AJ249217.gene.p01	34.4	343	386	349	3.46e-49	168
k141_121365_35	SARG|gb|BAH45481.1|ARO:3002815|clbB	35.1	345	386	343	8.21e-49	167
k141_121365_35	SARG|gb|AGZ55247.1|ARO:3002814|clbA	34.3	341	386	349	1.41e-47	164
k141_712071_2	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.4	339	1159	1197	4.74e-37	150
k141_712071_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	30.4	125	1159	225	5.80e-07	50.8
k141_712071_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	30.4	125	1159	225	5.80e-07	50.8
k141_712071_20	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.7	166	226	362	3.78e-10	57.8
k141_712071_28	CARD|gb|ALH22601.1|ARO:3000620|adeL	30.0	273	306	337	5.49e-31	117
k141_712071_39	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	36.0	322	322	325	2.02e-52	174
k141_712071_39	SARG|gb|AAA26793|ARO:3003748|oleC	36.3	320	322	325	4.00e-52	173
k141_712071_39	SARG|gi|542061059|gb|ERI11611.1|	41.3	223	322	316	2.44e-47	160
k141_712071_39	SARG|gi|500194536|ref|WP_011867743.1|	43.5	209	322	306	7.38e-47	159
k141_712071_39	SARG|P42332	42.6	209	322	306	4.05e-46	157
k141_712071_39	SARG|ABB80128	35.3	309	322	306	4.05e-46	157
k141_712071_39	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	42.6	209	322	306	4.05e-46	157
k141_712071_39	SARG|gi|445996719|ref|WP_000074574.1|	41.1	209	322	309	4.36e-46	157
k141_712071_39	SARG|gi|510143239|gb|AGN36970.1|	42.6	209	322	313	4.82e-46	157
k141_712071_39	SARG|ZP_04081918	42.6	209	322	306	7.99e-46	156
k141_712071_47	CARD|gb|AAK37618.1|ARO:3005008|TxR	32.1	330	471	318	5.27e-51	174
k141_712071_49	SARG|gb|AAV85982.1|ARO:3000535|macB	25.4	303	412	644	1.26e-16	80.9
k141_712071_49	SARG|gi|1035735809|ref|WP_064572349.1|	24.9	289	412	648	1.64e-14	74.3
k141_712071_49	SARG|gi|446110330|ref|WP_000188185.1|	24.9	289	412	648	9.09e-14	72.0
k141_712071_49	SARG|gi|485886761|ref|WP_001480338.1|	24.8	318	412	648	9.09e-14	72.0
k141_712071_49	SARG|gi|693170426|ref|WP_032302787.1|	24.9	289	412	648	1.21e-13	71.6
k141_712071_49	SARG|gi|742907943|ref|WP_039020462.1|	24.9	289	412	648	1.21e-13	71.6
k141_712071_49	SARG|gi|671541568|ref|WP_031525212.1|	24.6	289	412	648	1.21e-13	71.6
k141_712071_49	SARG|gi|446110310|ref|WP_000188165.1|	24.9	289	412	648	1.21e-13	71.6
k141_712071_49	SARG|gi|983413012|ref|WP_060578893.1|	24.7	291	412	646	2.13e-13	70.9
k141_712071_49	SARG|gi|692988230|ref|WP_032177097.1|	24.9	289	412	648	2.13e-13	70.9
k141_712071_50	SARG|gi|922019548|ref|WP_053299973.1|	47.9	219	221	648	2.46e-65	212
k141_712071_50	SARG|gi|555268037|ref|WP_023249477.1|	47.9	219	221	648	2.46e-65	212
k141_712071_50	SARG|YP_001571041	47.0	219	221	648	2.46e-65	212
k141_712071_50	SARG|gi|960873409|ref|WP_058345546.1|	47.0	219	221	648	2.46e-65	212
k141_712071_50	SARG|gi|924626178|ref|WP_053530123.1|	47.9	219	221	648	3.44e-65	211
k141_712071_50	SARG|gi|554685678|ref|WP_023185565.1|	48.4	219	221	648	4.81e-65	211
k141_712071_50	SARG|gi|740610794|ref|WP_038396317.1|	47.0	219	221	648	6.73e-65	211
k141_712071_50	SARG|gi|555246906|ref|WP_023230855.1|	47.9	219	221	648	9.41e-65	210
k141_712071_50	SARG|YP_002044935	47.9	219	221	648	9.41e-65	210
k141_712071_50	SARG|gi|835666879|ref|WP_047606339.1|	47.9	219	221	648	9.41e-65	210
k141_712071_51	SARG|gi|915797204|ref|WP_050892644.1|	22.0	413	417	392	1.70e-14	73.6
k141_712071_51	SARG|gi|844730941|ref|WP_047926220.1|	22.0	413	417	392	4.12e-13	69.3
k141_712071_51	SARG|gi|856831580|ref|WP_048339545.1|	21.6	416	417	392	5.50e-13	68.9
k141_712071_51	SARG|gi|489808654|ref|WP_003712515.1|	22.3	381	417	426	6.25e-13	68.9
k141_712071_51	SARG|gi|489793501|ref|WP_003697392.1|	22.3	413	417	392	7.35e-13	68.6
k141_712071_51	SARG|gi|728044173|ref|WP_033910180.1|	21.8	413	417	392	7.35e-13	68.6
k141_712071_51	SARG|gi|911859034|ref|WP_050157472.1|	22.3	413	417	392	7.35e-13	68.6
k141_712071_51	SARG|gi|844693715|ref|WP_047919963.1|	22.0	413	417	392	9.80e-13	68.2
k141_712071_51	SARG|gi|489796383|ref|WP_003700274.1|	22.0	413	417	392	1.31e-12	67.8
k141_712071_51	SARG|gi|752776007|ref|WP_041422998.1|	21.2	416	417	392	1.74e-12	67.4
k141_440967_36	SARG|gb|AEY83581|ARO:3000510|mupB	21.8	891	940	1033	1.08e-43	171
k141_440967_36	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	21.6	872	940	1033	1.89e-43	170
k141_440967_36	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	21.1	877	940	1024	9.64e-32	132
k141_440967_36	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	21.1	877	940	1024	9.64e-32	132
k141_440967_36	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	21.1	877	940	1024	1.67e-31	132
k141_440967_36	SARG|gb|CAA53189|ARO:3000521|mupA	21.1	877	940	1024	1.67e-31	132
k141_440967_43	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.6	116	283	219	1.25e-16	75.9
k141_440967_43	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.3	134	283	228	1.73e-14	70.1
k141_440967_43	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	32.5	114	283	233	2.05e-12	64.3
k141_440967_43	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.0	112	283	223	1.60e-09	55.8
k141_440967_43	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	114	283	232	3.94e-07	48.9
k141_440967_43	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	114	283	232	7.15e-07	48.1
k141_804688_1	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	35.0	383	355	703	1.85e-55	191
k141_418223_10	SARG|gi|928900436|ref|WP_053931243.1|	30.3	542	721	600	9.46e-58	205
k141_418223_10	SARG|gi|664579989|ref|WP_031094015.1|	30.3	542	721	601	9.63e-58	205
k141_418223_10	SARG|gi|702897513|ref|WP_033300957.1|	29.7	542	721	601	1.44e-54	196
k141_418223_10	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	25.0	364	721	579	7.08e-34	136
k141_418223_10	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	24.5	364	721	579	5.50e-33	133
k141_418223_10	SARG|gi|974588181|ref|WP_059178476.1|	33.5	185	721	646	5.46e-20	93.6
k141_418223_10	SARG|YP_001176128	33.5	185	721	646	5.46e-20	93.6
k141_418223_12	CARD|gb|AAD51347.1|ARO:3003067|smeS	33.1	130	223	467	8.86e-08	50.8
k141_418223_19	CARD|gb|AAG05188.1|ARO:3005068|ParR	39.7	239	240	235	6.38e-52	167
k141_418223_19	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	40.0	245	240	252	5.87e-51	165
k141_418223_19	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.8	231	240	228	8.30e-51	164
k141_418223_19	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	38.0	234	240	225	1.54e-47	155
k141_418223_19	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.1	236	240	219	1.03e-46	153
k141_418223_19	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.9	236	240	231	2.05e-46	153
k141_418223_19	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.4	236	240	231	5.77e-46	152
k141_418223_19	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.4	239	240	233	8.62e-46	151
k141_418223_19	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	36.6	238	240	231	1.15e-45	151
k141_418223_19	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.6	238	240	231	1.15e-45	151
k141_418223_20	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.8	237	407	359	7.20e-19	86.3
k141_372961_2	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	35.8	159	157	159	1.09e-23	89.7
k141_372961_31	CARD|gb|CAA79966.1|ARO:3003665|NmcR	30.6	297	295	295	2.11e-36	130
k141_281379_2	SARG|gi|445996729|ref|WP_000074584.1|	36.4	209	270	309	1.56e-35	128
k141_281379_2	SARG|gi|895808656|emb|COR83787.1|	36.4	209	270	309	1.56e-35	128
k141_281379_2	SARG|gi|895736250|emb|COF64653.1|	35.8	215	270	309	2.19e-35	127
k141_281379_2	SARG|gi|446110087|ref|WP_000187942.1|	35.8	215	270	309	2.19e-35	127
k141_281379_2	SARG|gi|507055561|ref|WP_016126482.1|	35.6	219	270	309	3.06e-35	127
k141_281379_2	SARG|gi|445996714|ref|WP_000074569.1|	35.8	215	270	309	3.06e-35	127
k141_281379_2	SARG|gi|1043490477|ref|WP_065382463.1|	35.2	219	270	309	6.00e-35	126
k141_281379_2	SARG|gi|445996726|ref|WP_000074581.1|	35.2	219	270	309	6.00e-35	126
k141_281379_2	SARG|gi|507050365|ref|WP_016121371.1|	35.1	225	270	309	6.00e-35	126
k141_281379_2	SARG|gi|445996723|ref|WP_000074578.1|	35.2	219	270	309	6.00e-35	126
k141_281379_16	CARD|gb|AAD51348.1|ARO:3003066|smeR	46.2	221	236	229	1.84e-62	194
k141_281379_16	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.0	222	236	228	1.86e-45	150
k141_281379_16	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.0	230	236	235	2.26e-45	150
k141_281379_16	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	40.6	234	236	252	5.09e-45	150
k141_281379_16	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	33.8	234	236	239	1.00e-44	149
k141_281379_16	CARD|gb|AAG05188.1|ARO:3005068|ParR	36.2	221	236	235	1.79e-44	148
k141_281379_16	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.3	230	236	233	6.73e-44	146
k141_281379_16	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.2	233	236	231	2.53e-43	145
k141_281379_16	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.2	233	236	231	2.53e-43	145
k141_281379_16	CARD|gb|ADM92605.1|ARO:3000553|adeR	36.5	230	236	247	5.51e-43	144
k141_281379_25	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.3	566	598	579	8.86e-84	272
k141_281379_25	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	33.4	566	598	579	2.70e-81	265
k141_281379_25	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	32.6	561	598	578	1.69e-76	253
k141_281379_25	SARG|gi|860594225|ref|WP_048475168.1|	31.1	579	598	620	1.77e-72	243
k141_281379_25	SARG|gi|917229923|ref|WP_051836635.1|	32.7	554	598	620	2.51e-71	240
k141_281379_25	SARG|gi|926376632|ref|WP_053705806.1|	31.3	576	598	620	2.51e-71	240
k141_281379_25	SARG|gi|496018010|ref|WP_008742581.1|	32.2	544	598	623	2.67e-71	240
k141_281379_25	SARG|gi|917203192|ref|WP_051809904.1|	31.3	576	598	620	3.50e-71	239
k141_281379_25	SARG|gi|799286378|ref|WP_045936958.1|	31.1	576	598	620	6.78e-71	239
k141_281379_25	SARG|gi|926294973|ref|WP_053631154.1|	31.1	576	598	620	6.78e-71	239
k141_281379_26	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	34.6	572	585	574	2.68e-99	312
k141_281379_26	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	33.0	581	585	579	1.08e-95	303
k141_281379_26	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	32.4	581	585	579	6.89e-93	295
k141_281379_26	SARG|gi|948137056|ref|WP_056795395.1|	32.0	547	585	602	5.14e-66	225
k141_281379_26	SARG|gi|817122037|ref|WP_046494699.1|	33.2	561	585	613	1.71e-65	224
k141_281379_26	SARG|gi|953808775|ref|WP_058042812.1|	32.0	553	585	608	5.70e-62	214
k141_281379_26	SARG|gi|664458452|ref|WP_030980047.1|	32.6	488	585	601	6.94e-62	214
k141_281379_26	SARG|gb|AAK76137.1|ARO:3000024|patA	28.9	567	585	564	1.24e-59	207
k141_281379_26	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.9	486	585	664	2.71e-59	208
k141_281379_26	SARG|gb|AAK76136.1|ARO:3000025|patB	29.7	489	585	588	8.51e-54	191
k141_281672_2	SARG|gi|742384718|ref|WP_038863845.1|	50.9	218	224	647	1.96e-71	228
k141_281672_2	SARG|gi|696411918|ref|WP_032982657.1|	50.9	218	224	647	1.96e-71	228
k141_281672_2	SARG|gi|742378414|ref|WP_038857601.1|	51.4	218	224	647	1.96e-71	228
k141_281672_2	SARG|gi|495004199|ref|WP_007730213.1|	50.9	218	224	647	7.55e-71	226
k141_281672_2	SARG|gi|742409107|ref|WP_038888226.1|	50.9	218	224	647	7.55e-71	226
k141_281672_2	SARG|gi|736472622|ref|WP_034494292.1|	50.5	218	224	648	7.69e-71	226
k141_281672_2	SARG|gi|696402390|ref|WP_032974230.1|	50.5	218	224	647	1.06e-70	226
k141_281672_2	SARG|gi|696423952|ref|WP_032993748.1|	50.5	218	224	647	1.06e-70	226
k141_281672_2	SARG|gi|1035670474|ref|WP_064517458.1|	50.5	218	224	648	1.08e-70	226
k141_281672_2	SARG|gi|1035717981|ref|WP_064557480.1|	50.5	218	224	648	1.08e-70	226
k141_281672_4	SARG|gi|755158529|ref|WP_042508254.1|	24.7	158	427	426	2.37e-07	51.6
k141_281672_5	SARG|gi|1035670474|ref|WP_064517458.1|	31.2	407	412	648	2.88e-41	153
k141_281672_5	SARG|gi|1035717981|ref|WP_064557480.1|	31.2	407	412	648	2.88e-41	153
k141_281672_5	SARG|gi|736472622|ref|WP_034494292.1|	31.0	407	412	648	1.90e-40	151
k141_281672_5	SARG|gb|AAV85982.1|ARO:3000535|macB	30.4	411	412	644	3.45e-40	150
k141_281672_5	SARG|gi|1035706844|ref|WP_064548272.1|	30.2	407	412	648	2.33e-39	148
k141_281672_5	SARG|gi|657888313|ref|WP_029592374.1|	30.7	407	412	648	3.18e-39	147
k141_281672_5	SARG|gi|639218559|ref|WP_024556062.1|	30.7	407	412	648	3.18e-39	147
k141_281672_5	SARG|gi|896325272|ref|WP_049294291.1|	30.2	407	412	648	3.18e-39	147
k141_281672_5	SARG|gi|639216333|ref|WP_024554080.1|	30.2	407	412	648	3.18e-39	147
k141_281672_5	SARG|gi|639225329|ref|WP_024561799.1|	30.7	407	412	648	4.35e-39	147
k141_281672_9	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	33.3	120	455	229	1.22e-12	66.2
k141_281672_9	CARD|gb|ADM92605.1|ARO:3000553|adeR	28.6	119	455	247	9.48e-12	63.9
k141_281672_9	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	27.4	117	455	232	2.63e-07	50.4
k141_281672_9	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	27.4	117	455	232	2.63e-07	50.4
k141_170891_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.6	219	226	219	6.80e-55	174
k141_170891_8	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	41.3	218	226	228	4.60e-52	167
k141_170891_8	CARD|gb|AAG06465.1|ARO:3005063|cprR	38.4	219	226	223	3.67e-47	154
k141_170891_8	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	36.2	221	226	233	3.08e-45	149
k141_170891_8	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	221	226	219	6.59e-44	145
k141_170891_8	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	221	226	219	2.62e-43	144
k141_170891_8	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	221	226	220	2.70e-43	144
k141_170891_8	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	221	226	220	3.81e-43	144
k141_170891_8	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.7	228	226	231	1.45e-42	142
k141_170891_8	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	221	226	220	3.02e-42	141
k141_170891_11	CARD|gb|AAC75136.1|ARO:3000793|mdtB	25.6	1033	1070	1040	1.54e-73	263
k141_170891_11	CARD|gb|AAC75137.1|ARO:3000794|mdtC	24.5	1036	1070	1025	9.05e-72	258
k141_170891_11	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	25.0	1085	1070	1074	5.05e-70	253
k141_170891_11	SARG|gb|AAG05914|ARO:3004075|MuxC	24.8	1037	1070	1036	1.41e-67	245
k141_170891_11	SARG|gb|CAH14033.1|ARO:3004100|LpeB	24.9	1044	1070	1014	2.13e-67	244
k141_170891_11	SARG|gb|AAG05915.1|ARO:3004074|MuxB	24.7	1023	1070	1043	3.86e-66	241
k141_170891_11	SARG|YP_001350280	24.1	1043	1070	1018	6.40e-64	234
k141_170891_11	SARG|gb|BAE06006.1|ARO:3003705|mexN	24.3	1038	1070	1036	7.28e-64	234
k141_170891_11	SARG|AAG07763	24.1	1046	1070	1018	1.54e-63	233
k141_170891_11	SARG|YP_792720	24.1	1046	1070	1018	2.77e-63	232
k141_170891_16	SARG|gb|AML99881.1|ARO:3001327|mdtK	27.5	436	488	474	8.33e-34	132
k141_353513_19	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.1	527	1491	1197	5.95e-52	199
k141_353513_19	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.0	115	1491	219	3.37e-09	57.8
k141_353513_19	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.2	116	1491	219	4.54e-09	57.4
k141_353513_19	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.2	116	1491	219	4.54e-09	57.4
k141_353513_19	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.2	116	1491	220	4.60e-09	57.4
k141_353513_19	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.2	116	1491	220	6.21e-09	57.0
k141_353513_19	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.3	116	1491	220	1.22e-07	53.1
k141_353513_20	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.8	117	321	229	4.36e-20	86.3
k141_353513_20	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	38.5	117	321	235	1.77e-19	84.7
k141_353513_20	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.9	116	321	233	1.61e-18	82.0
k141_353513_20	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.1	119	321	228	3.84e-18	80.9
k141_353513_20	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.9	117	321	231	1.99e-17	79.0
k141_353513_20	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.9	117	321	231	2.74e-17	78.6
k141_353513_20	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	35.8	123	321	239	3.13e-17	78.6
k141_353513_20	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.9	117	321	231	3.76e-17	78.2
k141_353513_20	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.0	123	321	230	5.08e-17	77.8
k141_353513_20	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.3	116	321	232	7.21e-17	77.4
k141_353513_33	SARG|AB084246.gene.p01	34.4	180	409	401	7.00e-20	89.7
k141_353513_33	SARG|gi|610425508|gb|AHW74384.1|	34.4	180	409	406	7.26e-20	89.7
k141_353513_33	NCBI|WP_001089072.1|1|1|tet(B)|tet(B)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_MFS_transporter_Tet(B)|AMR|tetracycline	33.9	180	409	401	2.32e-19	88.2
k141_353513_33	SARG|ABW39616	33.9	180	409	401	2.32e-19	88.2
k141_353513_33	SARG|BAC67138	33.9	180	409	401	2.32e-19	88.2
k141_353513_33	SARG|V00611.gene.p01	33.9	180	409	401	2.32e-19	88.2
k141_353513_33	SARG|BAC67143	33.9	180	409	401	4.21e-19	87.4
k141_353513_33	SARG|AF326777.3.gene20.p01	34.6	182	409	401	5.68e-19	87.0
k141_353513_33	SARG|YP_002394587	34.6	182	409	417	6.31e-19	87.0
k141_353513_33	NCBI|WP_063964002.1|1|1|tet(B)|tet(B)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_MFS_transporter_Tet(B)|AMR|tetracycline	33.3	180	409	401	7.65e-19	86.7
k141_59655_18	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.2	131	1201	219	7.24e-11	62.4
k141_59655_18	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.2	131	1201	219	7.24e-11	62.4
k141_59655_18	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.2	131	1201	220	7.35e-11	62.4
k141_59655_18	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.2	131	1201	220	9.93e-11	62.0
k141_59655_18	SARG|ZP_02848503	28.8	132	1201	221	1.84e-10	61.2
k141_59655_18	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.2	131	1201	220	8.11e-10	59.3
k141_59655_18	CARD|gb|AAG06465.1|ARO:3005063|cprR	28.5	137	1201	223	1.24e-08	55.8
k141_59655_18	CARD|gb|ATC67679.1|ARO:3000838|arlR	31.8	107	1201	219	2.31e-07	52.0
k141_59655_24	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.1	199	1361	359	1.95e-09	60.1
k141_59655_24	CARD|gb|AEX49906.1|ARO:3003583|basS	32.2	143	1361	477	3.84e-09	59.7
k141_59655_24	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	32.1	109	1361	364	1.44e-08	57.4
k141_59655_24	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	32.1	109	1361	364	1.44e-08	57.4
k141_919468_1	CARD|gb|AAK37618.1|ARO:3005008|TxR	38.8	312	532	318	6.23e-53	181
k141_559177_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.8	290	736	582	5.19e-40	154
k141_559177_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.0	223	736	664	9.01e-27	115
k141_559177_3	SARG|gb|AAK76136.1|ARO:3000025|patB	29.8	228	736	588	2.01e-26	113
k141_559177_3	SARG|FR772051.1.gene9.p01	25.4	280	736	524	9.88e-06	47.8
k141_763359_8	SARG|gi|446026113|ref|WP_000103968.1|	28.4	222	286	306	4.13e-19	84.3
k141_763359_8	SARG|gi|445996710|ref|WP_000074565.1|	27.0	278	286	309	8.08e-19	83.6
k141_763359_8	SARG|YP_001373621	26.8	291	286	318	8.95e-19	83.6
k141_763359_8	SARG|gi|445996714|ref|WP_000074569.1|	26.6	278	286	309	2.09e-18	82.4
k141_763359_8	SARG|gi|507044560|ref|WP_016115614.1|	27.9	222	286	306	3.80e-18	81.6
k141_763359_8	SARG|gi|895736250|emb|COF64653.1|	26.6	278	286	309	3.93e-18	81.6
k141_763359_8	SARG|gi|814314593|emb|CKF49145.1|	26.6	278	286	309	7.37e-18	80.9
k141_763359_8	SARG|gi|445996719|ref|WP_000074574.1|	26.7	281	286	309	1.01e-17	80.5
k141_763359_8	SARG|gi|446110087|ref|WP_000187942.1|	26.3	278	286	309	1.01e-17	80.5
k141_763359_8	SARG|gi|445996709|ref|WP_000074564.1|	26.6	278	286	309	1.89e-17	79.7
k141_128618_8	SARG|gi|497748188|ref|WP_010062372.1|	33.9	605	615	605	4.53e-85	276
k141_128618_8	SARG|gi|1045390184|ref|WP_065479071.1|	34.0	605	615	605	8.87e-85	276
k141_128618_8	SARG|gi|695865802|ref|WP_032778631.1|	33.9	605	615	605	2.43e-84	275
k141_128618_8	SARG|gi|695887424|ref|WP_032788534.1|	34.0	606	615	605	6.66e-84	273
k141_128618_8	SARG|gi|664180077|ref|WP_030714054.1|	33.9	605	615	605	6.66e-84	273
k141_128618_8	SARG|gi|664085850|ref|WP_030624018.1|	33.7	605	615	605	1.30e-83	273
k141_128618_8	SARG|gi|764446018|ref|WP_044369325.1|	33.7	605	615	605	1.82e-83	272
k141_128618_8	SARG|gi|662129758|ref|WP_030081404.1|	33.6	605	615	605	6.98e-83	271
k141_128618_8	SARG|gi|663342223|ref|WP_030341347.1|	33.6	605	615	605	1.91e-82	270
k141_128618_8	SARG|gi|664194237|ref|WP_030727956.1|	33.6	605	615	605	1.91e-82	270
k141_128618_33	CARD|gb|ALH22601.1|ARO:3000620|adeL	33.6	283	293	337	5.35e-41	144
k141_128618_33	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	24.5	265	293	291	6.68e-10	57.8
k141_128618_61	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.0	309	312	343	1.94e-46	159
k141_128618_61	SARG|gi|488120365|ref|WP_002191762.1|	25.9	305	312	309	1.97e-29	113
k141_128618_61	SARG|gi|445996710|ref|WP_000074565.1|	25.6	305	312	309	3.81e-29	112
k141_128618_61	SARG|gi|445996719|ref|WP_000074574.1|	25.9	305	312	309	5.29e-29	112
k141_128618_61	SARG|gi|487936534|ref|WP_002010000.1|	25.9	305	312	309	5.29e-29	112
k141_128618_61	SARG|gi|445996714|ref|WP_000074569.1|	25.6	305	312	309	5.29e-29	112
k141_128618_61	SARG|gi|895736250|emb|COF64653.1|	25.6	305	312	309	7.36e-29	111
k141_128618_61	SARG|gi|445996708|ref|WP_000074563.1|	25.9	305	312	309	7.36e-29	111
k141_128618_61	SARG|gi|488068784|ref|WP_002140181.1|	26.2	305	312	309	7.36e-29	111
k141_128618_61	SARG|gi|507023808|ref|WP_016095885.1|	25.9	305	312	309	1.02e-28	111
k141_128618_67	SARG|gb|ADZ12699.1|ARO:3005091|RanA	32.6	239	269	258	6.74e-40	138
k141_128618_67	SARG|gi|585358510|ref|WP_024240108.1|	31.8	242	269	648	1.02e-24	102
k141_128618_67	SARG|gb|AAC74000.1|ARO:3003950|msbA	29.6	240	269	582	5.33e-20	88.2
k141_128618_67	SARG|gi|817122037|ref|WP_046494699.1|	31.7	240	269	613	2.76e-18	83.2
k141_128618_67	SARG|gi|664170108|ref|WP_030704355.1|	28.3	251	269	603	3.70e-18	82.8
k141_128618_67	SARG|gi|490068471|ref|WP_003970646.1|	28.3	251	269	603	3.70e-18	82.8
k141_128618_67	SARG|gi|764446018|ref|WP_044369325.1|	29.1	251	269	605	3.71e-18	82.8
k141_128618_67	SARG|gi|921231571|ref|WP_053176464.1|	30.5	239	269	620	3.75e-18	82.8
k141_128618_67	SARG|gi|496018010|ref|WP_008742581.1|	30.1	239	269	623	6.86e-18	82.0
k141_128618_67	SARG|gi|917229923|ref|WP_051836635.1|	28.8	260	269	620	9.25e-18	81.6
k141_423937_18	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	34.6	315	552	429	9.16e-59	200
k141_423937_30	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.3	123	197	392	1.27e-16	75.9
k141_423937_30	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	34.2	117	197	364	6.51e-15	70.9
k141_423937_30	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	34.2	117	197	364	6.51e-15	70.9
k141_423937_30	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	35.6	101	197	367	1.23e-14	70.1
k141_423937_30	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	35.6	101	197	368	1.23e-14	70.1
k141_423937_30	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	36.2	116	197	361	1.64e-14	69.7
k141_423937_30	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	36.2	116	197	361	1.64e-14	69.7
k141_423937_30	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	38.9	95	197	361	1.95e-13	66.6
k141_423937_30	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	38.9	95	197	361	1.95e-13	66.6
k141_423937_30	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	34.3	99	197	364	9.19e-13	64.7
k141_581920_41	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.7	188	202	204	1.07e-16	73.9
k141_581920_41	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.7	116	202	228	4.80e-06	44.7
k141_538547_19	CARD|gb|ALH22601.1|ARO:3000620|adeL	30.2	285	291	337	1.85e-34	126
k141_538547_46	SARG|AAV80410	29.7	451	556	651	7.43e-40	152
k141_538547_46	SARG|L42544.gene.p01	29.7	451	556	651	1.86e-39	151
k141_538547_46	SARG|AJ514254.gene.p01	26.0	465	556	640	2.65e-38	148
k141_538547_46	SARG|Q02652	29.8	456	556	639	1.36e-36	143
k141_538547_46	SARG|NP_348076	28.0	447	556	652	4.94e-36	141
k141_538547_46	SARG|YP_002850805	26.9	449	556	652	4.03e-35	139
k141_538547_46	SARG|L20800.gene.p01	27.1	447	556	652	7.33e-35	138
k141_538547_46	SARG|ZP_02632674	26.8	459	556	660	2.53e-34	136
k141_538547_46	SARG|CAA37477	27.8	464	556	663	2.57e-34	136
k141_538547_46	SARG|ZP_02952732	26.8	447	556	652	4.39e-34	135
k141_538547_65	SARG|gb|AAK76137.1|ARO:3000024|patA	27.7	206	369	564	1.00e-15	77.4
k141_538547_69	CARD|gb|AAG05188.1|ARO:3005068|ParR	29.3	123	260	235	1.38e-14	70.1
k141_538547_69	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	30.8	120	260	225	1.91e-12	63.9
k141_538547_69	CARD|gb|AAC73788.1|ARO:3003841|kdpE	30.8	120	260	225	1.91e-12	63.9
k141_220624_25	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.7	226	845	1197	1.41e-25	112
k141_129918_36	SARG|gi|981224618|ref|WP_059445588.1|	44.0	218	229	646	2.25e-53	180
k141_129918_36	SARG|gi|836585048|ref|WP_047742322.1|	44.0	218	229	646	2.25e-53	180
k141_129918_36	SARG|gi|779956086|ref|WP_045403603.1|	43.6	218	229	646	6.05e-53	179
k141_129918_36	SARG|gi|1016275448|gb|AMX06027.1|	43.6	218	229	646	6.05e-53	179
k141_129918_36	SARG|gi|922960663|ref|WP_053388845.1|	42.7	218	229	648	8.62e-53	179
k141_129918_36	SARG|gi|779866095|ref|WP_045354445.1|	43.6	218	229	646	1.17e-52	178
k141_129918_36	SARG|gi|757799695|ref|WP_043016897.1|	42.7	218	229	648	1.20e-52	178
k141_129918_36	SARG|gi|1045891604|ref|WP_065554100.1|	42.7	218	229	648	1.20e-52	178
k141_129918_36	SARG|gi|507082903|ref|WP_016153652.1|	42.7	218	229	648	1.20e-52	178
k141_129918_36	SARG|gi|696368937|ref|WP_032943949.1|	42.7	218	229	648	1.20e-52	178
k141_129918_39	SARG|gb|AAA25550.1|ARO:3003105|dfrA3	46.9	147	161	162	1.76e-43	140
k141_129918_39	NCBI|WP_012779617.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	42.5	160	161	163	1.47e-42	138
k141_129918_39	SARG|gb|CBL80435.1|ARO:3002869|dfrK	40.0	160	161	163	2.73e-40	132
k141_129918_39	NCBI|WP_031775848.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	40.0	160	161	163	2.73e-40	132
k141_129918_39	SARG|gb|BAE15963.1|ARO:3002868|dfrG	40.0	160	161	165	4.09e-40	132
k141_129918_39	SARG|CAL48457	39.2	166	161	183	9.75e-40	131
k141_129918_39	NCBI|WP_004729503.1|1|1|dfrA41|dfrA41|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA41|AMR|diaminopyrimidine	41.0	161	161	170	1.35e-39	130
k141_129918_39	SARG|gb|ASF80997.1|ARO:3005164|dfrA35	46.0	139	161	170	3.82e-39	129
k141_129918_39	SARG|gb|AAO04716.1|ARO:3002865|dfrC	38.6	158	161	161	1.18e-38	128
k141_129918_39	NCBI|WP_000175735.1|1|1|dfrS1|dfrC|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrS1|AMR|diaminopyrimidine	38.6	158	161	161	1.68e-38	127
k141_129918_54	SARG|gi|944470764|ref|WP_055701183.1|	34.8	584	747	601	9.78e-98	313
k141_129918_54	SARG|gi|664556405|ref|WP_031071225.1|	33.7	596	747	602	1.00e-97	313
k141_129918_54	SARG|gi|639892676|ref|WP_024755698.1|	34.2	588	747	631	1.09e-97	314
k141_129918_54	SARG|gi|947982677|ref|WP_056642336.1|	34.0	588	747	626	2.63e-97	313
k141_129918_54	SARG|gi|496018010|ref|WP_008742581.1|	34.8	575	747	623	3.40e-97	313
k141_129918_54	SARG|gi|944009777|ref|WP_055601444.1|	33.8	586	747	628	7.58e-97	312
k141_129918_54	SARG|AF170880.4.gene1.p01	34.3	575	747	615	2.91e-96	310
k141_129918_54	SARG|gi|558888514|ref|WP_023543283.1|	34.1	575	747	615	2.91e-96	310
k141_129918_54	SARG|gi|943938624|ref|WP_055567802.1|	33.7	590	747	602	5.69e-96	309
k141_129918_54	SARG|gi|917155568|ref|WP_051762280.1|	35.0	575	747	620	9.07e-96	309
k141_129918_66	CARD|gb|ALH22601.1|ARO:3000620|adeL	34.8	290	303	337	1.56e-48	164
k141_129918_79	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	31.2	125	567	384	4.26e-06	48.1
k141_129918_79	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	31.2	125	567	384	4.26e-06	48.1
k141_129918_79	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	31.2	125	567	386	7.49e-06	47.4
k141_129918_79	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	31.2	125	567	386	7.49e-06	47.4
k141_129918_86	SARG|gb|AAG07065.1|ARO:3003692|mexJ	36.0	347	392	367	1.27e-53	181
k141_129918_86	CARD|gb|AAG03547.1|ARO:3003680|TriB	33.2	343	392	356	9.58e-37	135
k141_129918_86	SARG|gi|959916034|ref|WP_058178276.1|	21.6	357	392	414	1.16e-08	55.5
k141_129918_86	SARG|gi|953545058|ref|WP_058019717.1|	21.6	357	392	414	1.16e-08	55.5
k141_129918_86	SARG|gi|553796994|ref|WP_023127580.1|	22.3	358	392	414	1.54e-08	55.1
k141_129918_86	SARG|gi|553792626|ref|WP_023123650.1|	21.6	357	392	414	1.54e-08	55.1
k141_129918_86	SARG|gi|730317264|ref|WP_033982913.1|	21.6	357	392	414	1.54e-08	55.1
k141_129918_86	SARG|gi|685895166|ref|WP_031636099.1|	21.6	357	392	414	1.54e-08	55.1
k141_129918_86	SARG|gi|730265746|ref|WP_033963465.1|	21.6	357	392	414	1.54e-08	55.1
k141_129918_86	SARG|gi|550043910|ref|WP_022580473.1|	21.6	357	392	414	1.54e-08	55.1
k141_129918_87	SARG|gb|AAG07064.1|ARO:3003693|mexK	52.2	1027	1035	1025	0.0	996
k141_129918_87	CARD|gb|AAG03548.1|ARO:3003681|TriC	43.7	1023	1035	1015	1.08e-281	812
k141_129918_87	SARG|gb|AAG05914|ARO:3004075|MuxC	25.5	1037	1035	1036	5.88e-63	231
k141_129918_87	SARG|YP_348488	25.0	1042	1035	1043	4.77e-62	228
k141_129918_87	ResF|tmexD3_1_LC633285_1	25.1	1042	1035	1044	2.12e-60	223
k141_129918_87	ResF|tmexD4_1_CP091084_1	25.2	1042	1035	1044	2.12e-60	223
k141_129918_87	NCBI|WP_034065037.1|1|1|tmexD3|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD3|AMR|tetracycline	25.1	1042	1035	1044	2.12e-60	223
k141_129918_87	NCBI|WP_027591160.1|1|1|tmexD2|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD2|AMR|tetracycline	25.3	1042	1035	1044	1.21e-59	221
k141_129918_87	NCBI|WP_118842627.1|1|1|tmexD1|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD1|AMR|tetracycline	25.2	1043	1035	1044	9.15e-59	218
k141_129918_87	SARG|CAY51926	24.2	1046	1035	1008	1.34e-58	218
k141_129918_104	CARD|gb|AAC75429.1|ARO:3000833|evgS	23.0	226	469	1197	1.38e-10	62.8
k141_129918_105	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.2	223	236	219	7.19e-43	143
k141_129918_105	CARD|gb|AAG06465.1|ARO:3005063|cprR	38.1	223	236	223	4.40e-39	134
k141_129918_105	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.4	226	236	219	3.11e-38	131
k141_129918_105	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.4	226	236	219	4.38e-38	131
k141_129918_105	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.4	226	236	220	4.50e-38	131
k141_129918_105	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.4	226	236	220	1.26e-37	130
k141_129918_105	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	33.8	222	236	231	1.68e-37	130
k141_129918_105	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	33.0	224	236	233	4.96e-37	129
k141_129918_105	CARD|gb|AAG05188.1|ARO:3005068|ParR	33.9	230	236	235	4.87e-34	121
k141_129918_105	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.4	229	236	231	9.51e-33	117
k141_129918_117	SARG|gi|1004359922|gb|AMP42228.1|	25.1	435	598	639	1.02e-27	117
k141_129918_117	SARG|gb|AMP42147.1|ARO:3004442|tet(W/N/W)	25.6	433	598	639	1.36e-27	116
k141_129918_117	SARG|AAL09826	26.3	437	598	639	3.21e-27	115
k141_129918_117	SARG|gi|104303742|gb|ABF72138.1|	25.8	434	598	639	1.80e-26	113
k141_129918_117	SARG|YP_594556	24.6	435	598	639	2.39e-26	112
k141_129918_117	SARG|ACI02041	24.9	434	598	639	3.19e-26	112
k141_129918_117	SARG|ABN80187	24.8	435	598	640	3.20e-26	112
k141_129918_117	SARG|WP_000691721.1	24.9	434	598	639	5.65e-26	111
k141_129918_117	SARG|ABC18245	24.9	434	598	639	5.65e-26	111
k141_129918_117	SARG|AAL30847	24.9	434	598	639	5.65e-26	111
k141_424634_11	SARG|gb|APB03219.1|ARO:3003986|TaeA	35.2	654	651	648	3.74e-117	363
k141_424634_11	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	513	651	655	1.64e-71	243
k141_424634_11	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	513	651	655	3.17e-71	242
k141_424634_11	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	513	651	655	3.17e-71	242
k141_424634_11	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	513	651	655	4.40e-71	241
k141_424634_11	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	513	651	655	6.11e-71	241
k141_424634_11	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	513	651	655	6.11e-71	241
k141_424634_11	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	513	651	655	6.11e-71	241
k141_424634_11	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	513	651	655	6.11e-71	241
k141_424634_11	SARG|gb|AKA86814|ARO:3003746|optrA	30.2	513	651	655	6.11e-71	241
k141_424634_40	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	34.6	130	273	233	2.97e-09	55.1
k141_424634_40	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	32.5	126	273	231	8.11e-08	50.8
k141_424634_40	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.6	121	273	228	2.63e-07	49.3
k141_424634_40	CARD|gb|ATC67679.1|ARO:3000838|arlR	23.8	185	273	219	6.02e-07	48.1
k141_424634_65	SARG|gi|803568669|ref|WP_046077412.1|	32.3	223	434	648	3.50e-22	98.2
k141_424634_65	SARG|gi|446110352|ref|WP_000188207.1|	32.3	223	434	648	3.50e-22	98.2
k141_424634_65	SARG|YP_002382193	32.3	223	434	648	3.50e-22	98.2
k141_424634_65	SARG|gi|803575554|ref|WP_046081557.1|	32.3	223	434	648	3.50e-22	98.2
k141_424634_65	SARG|gi|446110351|ref|WP_000188206.1|	32.3	223	434	648	3.50e-22	98.2
k141_424634_65	SARG|gi|542061059|gb|ERI11611.1|	29.9	224	434	316	3.55e-22	95.5
k141_424634_65	SARG|gi|835330218|ref|WP_047457825.1|	31.8	217	434	648	1.12e-21	96.7
k141_424634_65	SARG|YP_001453760	31.8	217	434	648	1.12e-21	96.7
k141_424634_65	SARG|gi|500194536|ref|WP_011867743.1|	29.5	234	434	306	1.43e-21	93.6
k141_424634_65	SARG|gi|488068784|ref|WP_002140181.1|	28.4	236	434	309	9.52e-21	91.3
k141_424634_67	CARD|gb|AAD51347.1|ARO:3003067|smeS	26.2	221	410	467	1.18e-16	80.5
k141_424634_84	SARG|gi|1036665709|ref|WP_064719478.1|	27.5	367	408	369	1.59e-22	97.1
k141_424634_84	SARG|gi|559226183|ref|WP_023581296.1|	28.3	329	408	369	1.85e-21	94.0
k141_424634_84	SARG|gi|506488663|ref|WP_015965124.1|	26.6	320	408	371	6.40e-21	92.4
k141_424634_84	SARG|gi|857587769|emb|CRL59467.1|	26.3	323	408	369	2.87e-20	90.5
k141_424634_84	SARG|gi|908734730|ref|WP_049857314.1|	26.6	319	408	371	2.93e-20	90.5
k141_424634_84	SARG|gi|1005724275|ref|WP_061708557.1|	26.3	319	408	371	2.93e-20	90.5
k141_424634_84	SARG|gi|857776688|emb|CRL63266.1|	26.7	322	408	358	8.66e-20	89.0
k141_424634_84	SARG|gi|501336065|ref|WP_012367700.1|	26.9	320	408	369	9.64e-20	89.0
k141_424634_84	SARG|gi|739066754|ref|WP_036938162.1|	25.7	323	408	369	9.64e-20	89.0
k141_424634_84	SARG|gi|970309907|ref|WP_058679282.1|	27.1	369	408	371	9.82e-20	89.0
k141_424634_85	SARG|gi|693054987|ref|WP_032223114.1|	43.0	237	247	648	2.12e-57	192
k141_424634_85	SARG|gi|1035706844|ref|WP_064548272.1|	44.1	220	247	648	1.13e-55	187
k141_424634_85	SARG|AAA50325	29.3	215	247	569	3.66e-10	58.5
k141_424634_87	SARG|gb|AAV85982.1|ARO:3000535|macB	24.9	245	390	644	1.35e-13	71.2
k141_424634_87	SARG|gi|695748190|ref|WP_032674455.1|	34.8	115	390	646	3.12e-06	48.1
k141_424634_87	SARG|gi|779866095|ref|WP_045354445.1|	34.8	115	390	646	3.12e-06	48.1
k141_424634_87	SARG|gi|544824889|ref|WP_021240890.1|	34.8	115	390	646	3.12e-06	48.1
k141_424634_87	SARG|gi|556487375|ref|WP_023335108.1|	34.8	115	390	646	3.12e-06	48.1
k141_424634_87	SARG|gi|779956086|ref|WP_045403603.1|	34.8	115	390	646	3.12e-06	48.1
k141_424634_87	SARG|gi|647640371|ref|WP_025912926.1|	34.8	115	390	646	3.12e-06	48.1
k141_424634_87	SARG|gi|695731723|ref|WP_032658224.1|	34.8	115	390	646	3.12e-06	48.1
k141_424634_87	SARG|gi|851931792|ref|WP_048222288.1|	34.8	115	390	646	3.12e-06	48.1
k141_424634_87	SARG|gi|765031087|ref|WP_044596899.1|	34.8	115	390	646	3.12e-06	48.1
k141_424634_99	SARG|gb|AAP82271|ARO:3004123|Burkholderia	38.4	99	449	374	1.89e-12	67.4
k141_946162_8	CARD|gb|AAC76296.1|ARO:3000656|AcrS	31.3	201	215	220	2.17e-28	105
k141_946162_8	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	30.1	209	215	210	3.67e-27	102
k141_946162_8	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	30.1	209	215	210	5.16e-27	101
k141_946162_9	NCBI|AAN29240.1|1|1|bepD|bepD|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_BepD|AMR|efflux	39.1	358	441	397	4.72e-68	221
k141_946162_9	NCBI|AAF14522.1|1|1|mexX|mexX|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_MexX|AMR|efflux	34.4	393	441	396	3.42e-58	195
k141_946162_9	SARG|gi|730328506|ref|WP_033986417.1|	33.3	384	441	383	2.10e-55	187
k141_946162_9	SARG|gi|553784544|ref|WP_023116004.1|	33.3	384	441	383	2.10e-55	187
k141_946162_9	SARG|gi|759812131|ref|WP_043509561.1|	33.3	384	441	383	2.95e-55	187
k141_946162_9	SARG|gi|960884274|ref|WP_058355529.1|	33.3	384	441	383	2.95e-55	187
k141_946162_9	SARG|gb|AAF42063.1|ARO:3000810|mtrC	31.8	374	441	412	3.03e-55	187
k141_946162_9	SARG|gi|759360203|ref|WP_043089708.1|	33.3	384	441	383	4.13e-55	186
k141_946162_9	SARG|gi|757606897|ref|WP_042853548.1|	33.3	384	441	383	4.13e-55	186
k141_946162_9	SARG|gi|730363577|ref|WP_033999646.1|	33.3	384	441	383	4.13e-55	186
k141_946162_10	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	54.0	1023	1074	1051	0.0	1042
k141_946162_10	CARD|gb|ABS43151.1|ARO:3000784|cmeB	47.3	1025	1074	1040	4.72e-314	897
k141_946162_10	NCBI|WP_254563251.1|1|1|cmeB_RE|cmeB_RE|efflux|2|FLORFENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_CmeB,_ciprofloxacin_and_phenicol_resistance_type|AMR|multidrug	47.6	1025	1074	1039	2.59e-313	895
k141_946162_10	SARG|CP000647.1.gene3710.p01	47.1	1036	1074	1036	2.42e-299	860
k141_946162_10	SARG|gi|817600173|ref|WP_046594139.1|	46.9	1039	1074	1037	2.50e-299	860
k141_946162_10	SARG|gi|694076105|ref|WP_032421853.1|	46.9	1036	1074	1036	3.42e-299	859
k141_946162_10	SARG|gi|556290479|ref|WP_023291164.1|	47.2	1036	1074	1036	9.69e-299	858
k141_946162_10	SARG|gi|496667122|ref|WP_009309612.1|	46.8	1036	1074	1036	9.69e-299	858
k141_946162_10	SARG|gi|817600095|ref|WP_046594084.1|	46.8	1039	1074	1037	1.00e-298	858
k141_946162_10	SARG|gi|447196024|ref|WP_001273280.1|	46.8	1039	1074	1037	1.42e-298	858
k141_946162_11	SARG|NC_008702.1.4607681.p01	36.3	466	482	469	1.74e-76	246
k141_946162_11	SARG|gb|BAM10414.1|ARO:3003039|oprA	36.5	460	482	467	9.78e-75	241
k141_946162_11	SARG|YP_001116030	36.8	476	482	517	5.14e-73	238
k141_946162_11	SARG|ZP_02904979	36.8	478	482	511	8.75e-73	238
k141_946162_11	SARG|YP_776581	36.8	478	482	513	9.18e-73	238
k141_946162_11	SARG|ZP_02889082	36.8	478	482	513	9.18e-73	238
k141_946162_11	SARG|YP_001811889	36.8	478	482	513	2.53e-72	236
k141_946162_11	SARG|YP_371057	36.7	479	482	511	3.38e-72	236
k141_946162_11	SARG|YP_001949526	36.1	482	482	511	3.38e-72	236
k141_946162_11	SARG|ZP_03583211	36.1	482	482	516	3.81e-72	236
k141_154175_20	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.8	241	495	381	5.23e-09	57.0
k141_154175_20	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.8	241	495	381	5.23e-09	57.0
k141_154175_20	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.2	241	495	381	1.22e-08	55.8
k141_154175_20	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.2	241	495	381	1.22e-08	55.8
k141_154175_20	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.8	241	495	381	1.62e-08	55.5
k141_154175_20	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.8	241	495	381	1.62e-08	55.5
k141_154175_20	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.4	241	495	381	2.16e-08	55.1
k141_154175_20	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.4	241	495	381	2.16e-08	55.1
k141_154175_20	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	21.0	243	495	381	2.07e-07	52.0
k141_154175_20	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	21.0	243	495	381	2.07e-07	52.0
k141_154175_21	CARD|gb|AAK37618.1|ARO:3005008|TxR	42.4	278	447	318	5.05e-59	195
k141_154175_24	SARG|Q83LR7	40.4	235	240	648	1.69e-56	189
k141_154175_24	SARG|gi|647325472|ref|WP_025760953.1|	40.4	235	240	648	1.69e-56	189
k141_154175_24	SARG|gi|647323678|ref|WP_025760497.1|	40.4	235	240	648	1.69e-56	189
k141_154175_24	SARG|gi|446110305|ref|WP_000188160.1|	40.4	235	240	648	3.28e-56	188
k141_154175_24	SARG|gi|446110301|ref|WP_000188156.1|	40.9	235	240	648	1.23e-55	187
k141_154175_24	SARG|gi|391288090|gb|EIQ46599.1|	40.9	235	240	645	1.65e-55	186
k141_154175_24	SARG|gi|446110279|ref|WP_000188134.1|	40.7	236	240	648	1.72e-55	186
k141_154175_24	SARG|gi|486420890|ref|WP_001612725.1|	40.4	235	240	648	1.72e-55	186
k141_154175_24	SARG|gi|1016547979|ref|WP_063116960.1|	40.7	236	240	648	2.39e-55	186
k141_154175_24	SARG|gi|919943616|ref|WP_052915800.1|	41.6	238	240	648	2.39e-55	186
k141_154175_25	SARG|gi|749639726|ref|WP_040241688.1|	25.8	360	423	371	1.13e-15	77.0
k141_154175_25	SARG|gi|1031874524|ref|WP_064189330.1|	25.6	360	423	371	1.51e-15	76.6
k141_154175_25	SARG|gi|742286387|ref|WP_038808052.1|	25.8	360	423	371	2.72e-15	75.9
k141_154175_25	SARG|gi|749533846|ref|WP_040169856.1|	25.6	360	423	371	3.64e-15	75.5
k141_154175_25	SARG|gi|694079011|ref|WP_032424286.1|	25.6	360	423	371	6.54e-15	74.7
k141_154175_25	SARG|gi|571248424|emb|CDL42177.1|	25.3	360	423	371	8.76e-15	74.3
k141_154175_25	SARG|gi|914216734|ref|WP_050532922.1|	25.6	360	423	371	8.76e-15	74.3
k141_154175_25	SARG|gi|556279329|ref|WP_023289004.1|	25.6	360	423	371	8.76e-15	74.3
k141_154175_25	SARG|gi|1044254487|emb|SBY98128.1|	25.8	360	423	371	8.76e-15	74.3
k141_154175_25	SARG|gi|490306252|ref|WP_004201357.1|	25.6	360	423	371	8.76e-15	74.3
k141_154175_42	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	42.2	1371	1369	1186	0.0	999
k141_154175_42	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	42.2	1371	1369	1186	0.0	999
k141_154175_42	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	42.9	1380	1369	1162	0.0	994
k141_561474_21	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	27.1	221	363	293	2.60e-18	83.2
k141_721650_29	NCBI|WP_162338672.1|1|1|blaPJM-2|blaPJM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PJM-2|AMR|beta-lactam	41.1	263	306	301	2.46e-74	229
k141_721650_29	NCBI|WP_213603971.1|1|1|blaPJM-1|blaPJM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PJM-1|AMR|beta-lactam	41.1	263	306	301	9.84e-74	228
k141_721650_29	SARG|gb|CAQ53840.1|ARO:3000853|AIM-1	39.6	288	306	303	2.13e-70	219
k141_721650_29	NCBI|WP_231869638.1|1|1|blaAIM-2|blaAIM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_AIM-2|AMR|beta-lactam	39.2	288	306	303	4.81e-69	216
k141_721650_29	SARG|gb|WP_122630831.1|ARO:3006864|CRD3-1	38.8	273	306	303	5.42e-68	213
k141_721650_29	NCBI|WP_038576754.1|1|1|blaMIM-1|blaMIM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_MIM-1|AMR|beta-lactam	39.7	267	306	299	2.71e-67	211
k141_721650_29	SARG|gb|AYD68552.1|ARO:3005018|LMB-1	39.5	258	306	304	7.05e-66	207
k141_721650_29	NCBI|WP_219860712.1|1|1|blaB3SU1-1|blaB3SU1|hydrolase|2|CEPHALOSPORIN|beta-lactam|subclass_B3_metallo-beta-lactamase_B3SU1-1|AMR|beta-lactam	40.4	260	306	303	1.37e-65	207
k141_721650_29	SARG|gb|WP_122630823.1|ARO:3006886|EVM-1	37.9	277	306	305	4.08e-65	206
k141_721650_29	SARG|EU408349.1.gene1.p01	37.9	290	306	305	2.30e-64	204
k141_721650_32	CARD|gb|BAB36671.1|ARO:3000832|evgA	34.1	85	246	204	2.26e-09	54.7
k141_721650_32	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	28.9	121	246	228	3.37e-08	51.6
k141_721650_32	CARD|gb|AAG05188.1|ARO:3005068|ParR	30.6	108	246	235	1.79e-06	46.6
k141_721650_41	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	40.1	222	256	343	4.28e-45	153
k141_721650_41	SARG|gi|445996719|ref|WP_000074574.1|	40.9	215	256	309	8.16e-44	149
k141_721650_41	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	37.8	225	256	307	1.54e-43	148
k141_721650_41	SARG|gi|895736250|emb|COF64653.1|	40.5	215	256	309	8.89e-43	146
k141_721650_41	SARG|gi|446110087|ref|WP_000187942.1|	40.5	215	256	309	8.89e-43	146
k141_721650_41	SARG|gi|445996710|ref|WP_000074565.1|	40.5	215	256	309	8.89e-43	146
k141_721650_41	SARG|gi|488120365|ref|WP_002191762.1|	40.0	215	256	309	1.25e-42	146
k141_721650_41	SARG|gi|445996714|ref|WP_000074569.1|	40.5	215	256	309	1.25e-42	146
k141_721650_41	SARG|gi|488068784|ref|WP_002140181.1|	40.0	215	256	309	1.25e-42	146
k141_721650_41	SARG|gi|488067981|ref|WP_002139378.1|	39.5	215	256	309	1.76e-42	145
k141_721650_62	SARG|gi|486458841|gb|EOE03251.1|	46.3	67	331	237	1.15e-08	53.9
k141_721650_80	NCBI|WP_063840466.1|1|1|ampC_Sliq-1|ampC_Sliq-1|hydrolase|2|CEPHALOSPORIN|beta-lactam|cephalosporin-hydrolyzing_class_C_beta-lactamase|AMR|beta-lactam	27.3	348	368	378	3.09e-32	123
k141_721650_80	SARG|gi|764984241|ref|WP_044550790.1|	27.3	348	368	378	2.99e-31	120
k141_721650_80	megares|MEG_730|Drugs|beta-lactam|Penicillin_binding_protein|AMPH_1	28.8	323	368	386	3.38e-31	120
k141_721650_80	SARG|HQ322612.1.gene1.p01	29.7	320	368	379	1.28e-27	110
k141_721650_80	NCBI|WP_394294899.1|1|1|blaDHA-34|blaDHA|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_DHA-34|AMR|beta-lactam	29.4	320	368	379	3.34e-27	109
k141_721650_80	SARG|gb|WP_109545068.1|ARO:3006467|DHA-26	29.4	320	368	379	4.59e-27	109
k141_721650_80	SARG|gb|WP_063860108.1|ARO:3002154|DHA-23	29.4	320	368	379	4.59e-27	109
k141_721650_80	SARG|gb|AHL39320.1|ARO:3002140|DHA-9	29.4	320	368	379	4.59e-27	109
k141_721650_80	SARG|Y16410.1.gene2.p01	29.4	320	368	379	6.30e-27	108
k141_721650_80	SARG|gb|AIT76103.1|ARO:3002148|DHA-17	29.4	320	368	379	6.30e-27	108
k141_721650_88	SARG|gb|BAE06006.1|ARO:3003705|mexN	36.2	69	86	1036	3.31e-07	45.1
k141_721650_88	NCBI|AAN38824.2|1|1|adeE|adeE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_AdeE|AMR|efflux	43.6	55	86	1036	2.17e-06	42.7
k141_721650_88	SARG|gi|966461601|ref|WP_058493954.1|	39.3	56	86	1054	4.06e-06	42.0
k141_721650_88	SARG|gi|966403553|ref|WP_058447148.1|	37.5	56	86	1058	5.55e-06	41.6
k141_721650_88	SARG|gi|966396486|ref|WP_058441292.1|	37.5	56	86	1063	5.55e-06	41.6
k141_721650_88	SARG|gi|966432980|ref|WP_058473413.1|	37.5	56	86	1070	5.55e-06	41.6
k141_721650_88	SARG|gi|644964905|ref|WP_025385660.1|	35.7	56	86	1056	7.59e-06	41.2
k141_721650_88	SARG|gi|654933144|ref|WP_028383500.1|	37.5	56	86	1063	7.59e-06	41.2
k141_721650_96	SARG|gb|CAA03986.1|ARO:3000343|tap	22.9	433	451	409	3.75e-10	60.5
k141_721650_99	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.8	104	273	231	2.93e-06	46.2
k141_721650_99	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.8	111	273	232	2.95e-06	46.2
k141_132636_22	CARD|gb|AAC73788.1|ARO:3003841|kdpE	31.4	121	241	225	1.14e-13	67.0
k141_132636_22	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	31.1	119	241	225	4.09e-13	65.5
k141_132636_22	CARD|gb|AAD51348.1|ARO:3003066|smeR	30.8	117	241	229	3.18e-10	57.4
k141_132636_23	CARD|gb|AEX49906.1|ARO:3003583|basS	29.7	246	785	477	5.46e-12	67.8
k141_132636_23	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	24.0	225	785	386	4.74e-10	61.2
k141_132636_23	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	24.4	225	785	386	4.74e-10	61.2
k141_132636_23	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	24.0	225	785	386	4.74e-10	61.2
k141_132636_23	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	24.4	225	785	386	4.74e-10	61.2
k141_132636_23	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	24.0	225	785	388	8.41e-10	60.5
k141_132636_23	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	24.0	225	785	388	8.41e-10	60.5
k141_132636_23	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	23.3	240	785	384	1.46e-09	59.7
k141_132636_23	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	23.3	240	785	384	1.46e-09	59.7
k141_132636_23	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	20.4	260	785	359	3.52e-06	48.9
k141_132636_32	CARD|gb|AAG05188.1|ARO:3005068|ParR	31.6	117	262	235	2.00e-09	55.5
k141_132636_32	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.8	107	262	228	3.94e-08	51.6
k141_993466_34	SARG|FJ349556.1.gene5.p01	25.0	296	320	326	1.36e-19	86.7
k141_993466_34	SARG|gb|AAB05626.1|ARO:3002943|vanHB	24.6	289	320	323	2.63e-17	80.1
k141_993466_34	SARG|Q47748	24.6	289	320	323	4.88e-17	79.3
k141_993466_34	SARG|gi|985522333|ref|WP_060811962.1|	24.2	289	320	323	1.67e-16	77.8
k141_993466_34	SARG|gi|498515089|ref|WP_010815296.1|	24.2	289	320	323	3.09e-16	77.0
k141_993466_36	CARD|gb|VWQ00850.1|ARO:3003843|leuO	27.4	307	323	314	7.34e-30	114
k141_858112_19	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.8	231	236	231	5.61e-51	164
k141_858112_19	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.4	232	236	232	3.26e-50	162
k141_858112_19	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.4	232	236	232	3.26e-50	162
k141_858112_19	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.2	232	236	232	3.29e-47	155
k141_858112_19	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	36.6	238	236	239	8.01e-47	154
k141_858112_19	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.2	231	236	233	2.14e-45	150
k141_858112_19	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.1	232	236	235	3.19e-45	150
k141_858112_19	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.5	227	236	228	3.70e-45	149
k141_858112_19	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.8	230	236	232	3.28e-44	147
k141_858112_19	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	236	231	6.36e-44	146
k141_858112_20	CARD|gb|AAD51347.1|ARO:3003067|smeS	27.3	348	496	467	1.43e-28	117
k141_858112_20	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	29.1	213	496	357	1.41e-23	100
k141_858112_20	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	29.1	213	496	357	1.41e-23	100
k141_858112_20	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	22.8	237	496	341	3.29e-13	69.7
k141_474648_1	megares|MEG_1246|Drugs|beta-lactam|Class_A_betalactamases|BLAA_1	66.3	196	225	339	1.84e-97	286
k141_474648_5	CARD|gb|AAD51348.1|ARO:3003066|smeR	46.2	221	237	229	2.58e-57	181
k141_474648_5	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.2	228	237	232	2.14e-45	150
k141_474648_5	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.2	228	237	232	2.14e-45	150
k141_474648_5	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.2	229	237	232	3.39e-44	147
k141_474648_5	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.6	218	237	228	8.53e-44	146
k141_474648_5	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.4	226	237	231	4.10e-42	142
k141_474648_5	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.4	226	237	231	4.10e-42	142
k141_474648_5	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.4	226	237	231	2.29e-41	140
k141_474648_5	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.4	226	237	231	3.24e-41	139
k141_474648_5	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.4	226	237	231	4.56e-41	139
k141_474648_6	CARD|gb|AAD51347.1|ARO:3003067|smeS	40.8	387	536	467	7.43e-80	256
k141_474648_6	CARD|gb|ADM92606.1|ARO:3000549|adeS	32.3	279	536	361	2.53e-34	132
